Vitamin D Clinical Relevance in the Recovery From Traumatic Brain Injury Among the Military Population by Colón, Yuisa M.
University of Central Florida 
STARS 
Honors Undergraduate Theses UCF Theses and Dissertations 
2016 
Vitamin D Clinical Relevance in the Recovery From Traumatic 
Brain Injury Among the Military Population 
Yuisa M. Colón 
University of Central Florida 
 Part of the Behavioral Neurobiology Commons, Cognitive Neuroscience Commons, Medicine and 
Health Commons, Military and Veterans Studies Commons, Molecular and Cellular Neuroscience 
Commons, Neurology Commons, Neurosciences Commons, and the Trauma Commons 
Find similar works at: https://stars.library.ucf.edu/honorstheses 
University of Central Florida Libraries http://library.ucf.edu 
This Open Access is brought to you for free and open access by the UCF Theses and Dissertations at STARS. It has 
been accepted for inclusion in Honors Undergraduate Theses by an authorized administrator of STARS. For more 
information, please contact STARS@ucf.edu. 
Recommended Citation 
Colón, Yuisa M., "Vitamin D Clinical Relevance in the Recovery From Traumatic Brain Injury Among the 
Military Population" (2016). Honors Undergraduate Theses. 97. 
https://stars.library.ucf.edu/honorstheses/97 
  
 
 
 
 
 
 
 
 
 
 
VITAMIN D CLINICAL RELEVANCE IN THE RECOVERY FROM  
TRAUMATIC BRAIN INJURY AMONG THE MILITARY POPULATION 
 
 
by 
 
YUISA M. COLÓN 
 
A thesis submitted in partial fulfillment of the requirements 
for the Honors in the Major Program in Nursing 
in the College of Nursing 
and in The Burnett Honors College 
at the University of Central Florida 
Orlando, Florida 
 
Summer Term, 2016 
 
Thesis Chair: Susan K. Chase, EdD, RN, FNP-BC, FNAP 
 
  
ii 
 
 
 
 
 
 
 
 
 
 
© 2016 Yuisa M. Colón 
 
 
 
 
The images containing this symbol are work of the author and licensed under the Creative 
Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy 
of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.   
iii 
 
ABSTRACT 
Background: Traumatic brain injury (TBI) still remains a difficult disorder to treat. TBI has been 
associated to chronic neuroinflammation and a high risk for neurodegenerative disorders. Since 
2001 between ten to twenty percent of all deployed military members have suffered a combat-
related TBI. Nearly twenty to thirty percent of those will experience chronic cognitive, 
behavioral and somatic symptoms after suffering a TBI. 
Methods: The objective of this review is to evaluate current literature examining vitamin D as a 
neurosteroid with protective properties and its clinical relevance after traumatic brain injury. 
Vitamin D is known to participate in neurobiological processes and genomic regulation in the 
brain. Clinical and laboratory findings support that vitamin D modulates the immune responses 
to trauma, diminishes oxidative and toxic damage, and inhibiting activation and progression of 
the neuroinflammation. Inadequate levels of vitamin D have been identified as a common risk 
factor for many neurological disorders and have been linked to poorer recovery.  
Results: This review found compelling evidence to support that the pathology of TBI is closely 
associated with neuroprotective mechanisms of vitamin D. Low vitamin D levels are common 
among US active duty military and veterans. The findings strongly suggest that optimizing 
vitamin D prior to injury could improve the recovery for military members after experiencing a 
TBI. Vitamin D ameliorates brain damage by modulating neuroinflammation, improving cell 
survival and down-regulating mechanisms involved in the progression of cell damage following 
a TBI. However, further studies are needed to evaluate the effects of vitamin D optimization in 
TBI outcomes. 
Keywords: vitamin D, low vitamin D, neuroprotection, traumatic brain injury, TBI  
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CHAPTER 1:  INTRODUCTION 
Traumatic brain injury is characterized as a complex and multidimensional neurological 
disorder (Brain Trauma Foundation [BTF], 2007; Institute of Medicine [IOM], 2011a; Stein, 
2015). The onset of tissue and cellular alterations of TBIs emerge over a short period of time, but 
the consequences of the acute tissue damage has been known to predispose patients to other 
chronic neurological disorders, and shortens their lifespan (Chauhan, 2014; Daneshvar, 
Goldstein, Kiernan, Stein, & McKee, 2015; Gardner & Yaffe, 2015).  
Neurological disorders are complex. Uncertainty about the ideal management is related to 
unclear or poorly understood mechanisms and an assortment of environmental, genetic and 
physiological risk factors that amplify the uniqueness of the clinical presentations and 
progression. In addition to this complexity, the diversity of outcome measures further 
complicates the clinical picture (Maas et al., 2012; Groves, McGrath & Burne, 2014; Veterans 
Affairs and Department of Defense [VA/DoD], 2016). Interestingly, a newly identified common 
risk factor shared by many of the disorders is inadequate vitamin D levels. After correcting for 
confounding variants, researchers have found that the incidence and symptom severity of 
neuropsychiatric and neurodegenerative disorders remains higher for subjects with low levels of 
vitamin D (Groves, McGrath & Burne, 2014).  
In the last two decades, mounting epidemiologic evidence suggests that inadequate levels 
of vitamin D may be associated with an elevated risk for brain disorders such as schizophrenia 
(Cui et el., 2014; Groves, McGrath & Burne, 2014; Wrzosek et al., 2013), depression (Groves, 
McGrath & Burne, 2014), autism, Parkinson’s disease (Cui et el., 2014; Groves, McGrath & 
Burne, 2014), Alzheimer’s disease (Daneshvar et al., 2015; Groves, McGrath & Burne, 2014), 
2 
 
epilepsy (Groves, McGrath & Burne, 2014; Wrzosek et al., 2013), and brain atrophy (Annweiler, 
Annweiler, Montero-Odasso, Bartha & Beauchet, 2014; Wrzosek et al., 2013). The range of 
issues related to vitamin D deficiency speaks to a basic cellular set of activities that affect the 
entire system. 
Animal experiments and in-vitro studies have shown and described some of the 
underlying mechanisms that produce the neuroprotective activities of vitamin D on brain cells. 
Vitamin D is capable of modulating inflammatory cytokines (Groves, McGrath & Burne, 2014; 
Holick, 2007; Moromizato et al., 2013; Wrzosek et al., 2013), offers antioxidant benefits (Eyles, 
Burne & McGrath, 2013; Wrzosek et al., 2013), intracellular calcium regulation (Annweiler et 
al., 2014; Cui et el., 2014; Eyles, Burne & McGrath, 2013; Groves, McGrath & Burne, 2014; 
Wrzosek et al., 2013), neurotrophic enhancement (Annweiler et al., 2014; Eyles, Burne & 
McGrath, 2013; Groves, McGrath & Burne, 2014; Wrzosek et al., 2013), protection of the BBB 
integrity (Moromizato et al., 2013; Won et al., 2015), and may reduce the toxic damage from 
proteins exiting damaged cells (Atif et al., 2013; Huang, Ho, Lai, Chiu, & Wang, 2015; Kajta et 
al., 2009).  
This review will evaluate the literature to determine whether or not there is compelling 
evidence to support that vitamin D exerts a neuroprotective action in the acute phase following a 
traumatic brain injury (TBI). There is preliminary evidence that low vitamin D is prominent 
among active duty military (Alazzeh et al., 2015; Andersen et al., 2010; Bailey, Manning & 
Peiris, 2012; Hiserote et al., 2016; Wentz, Eldred, Henry, & Berry-Caban, 2014), a population 
with high prevalence of combat injuries involving trauma to the head (Bryan, 2013; Chauhan, 
2014; IOM, 2011a; McKee & Robinson, 2014; Twamley, Jak, Delis, Bondi, & Lohr, 2014; 
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Troyanskaya et al., 2015; Department of Veterans Affairs & Department of Defense [VA/DoD], 
2016; Vakhtin et al., 2013). This paper develops an argument for further investigation regarding 
the potential protective effect of vitamin D optimization on recovery from TBI, particularly for 
military personnel. 
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CHAPTER 2: METHODOLOGY 
Due to the lack of studies evaluating the existence of a relationship between vitamin D 
and TBI, this review focused on articles concerning the neuroprotective effect of vitamin D on 
brain tissue. Publications were identified via Ebsco on the following databases: Medline, Cinahl 
Plus, Academic Search Premier, Conchrane Controlled Trials and Conchrane Systematic 
Reviews. Terms used for the initial search parameters included: inflammatory cytokines, or 
neuroinflammat*, or neuron* disruption or blood-brain barrier or BBB or BBB leakage or 
membrane leakage or L-type calcium channels or calcium channel or brain intracellular calcium 
or reactive oxygen species or ROS or oxidative stress or neurodegene* or ion gradients or 
excitotoxic* or cerebral edema or neuroedema or apoptosis or neurotrophic or lipid peroxidation 
or hypoxi* or vitamin d receptor or VDR or antioxidant or neuroprotect* or regulat* or modulat* 
or cytotoxic* or neuroprotective agent. Additionally, two different groups of terms were used to 
narrow down the specificity of the results; one using multiple terms for vitamin D and the other 
for TBI (full list of terms is available on Appendix A). Results were limited to publications in 
English, between 2006 and 2016.  
Titles and abstracts were screened for inclusion/exclusion criteria with 14 articles 
selected. Duplicates across databases were removed during initial screening. The exclusion 
criteria included: (1) studies related to science or medical specialties other than neurology; (2) 
sample size of 1 patient; (3) age group: neonates, child* or infant or embryonic or pediatric or 
adolesce* or 0-18 years or birth or pregnancy or aged or aging or elderly or over 65; (4) did not 
include at least one of the topics from the inclusion criteria.  
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The inclusion criteria encompassed the following: (1) vitamin D neuroprotective effects 
in brain/axonal/neuronal injuries through mechanisms involving (2) neuroinflammation, blood-
brain barrier integrity, L-type calcium channel, oxidative stress/reactive oxygen species (ROS) 
and excitotoxicity. Of the articles that met the inclusion criteria included 11 were primary 
research articles/animal model experiments, 1 randomized control trials (RCT) and 2 literature 
reviews.  
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CHAPTER 3: TRAUMATIC BRAIN INJURY BACKGROUND 
Traumatic Brain Injury (TBI) comes in many forms. The characterization and definition 
of TBI is still yet to reach consensus (Gardner & Yaffe, 2015; Stein, 2015; VA/DoD, 2016). This 
should not come as a surprise, considering that the multidimensionality of the disorder results in 
a substantial assortment of clinical signs and symptoms severity, structural and functional 
alterations and heterogeneity of outcomes (BTF, 2007; IOM, 2011a; Stein, 2015). The most 
recent VA/DoD practice guidelines state that regardless of a confirmed exposure to an external 
force, a positive TBI diagnosis requires the reporting of one or more of the TBI clinical criteria 
immediately after sustaining an injury (VA/DoD, 2016). 
Traumatic brain injuries occur after a person suffers an external blow to the head and the 
severity can range from mild (concussion symptoms) to severe (coma) (World Health 
Organization [WHO], 2006). The U.S. Centers for Disease Control and Prevention (CDC) and 
the Department of Defense (DoD) defined TBI as: 
a traumatically induced structural injury and/or physiological disruption of brain function 
as a result of an external force and is indicated by new onset or worsening of at least one 
of the following clinical signs immediately following the event: (1) any period of loss of 
or a decreased level of consciousness; (2) any loss of memory for events immediately 
before or after the injury (posttraumatic amnesia); (3) any alteration in mental state at the 
time of the injury (e.g., confusion, disorientation, slowed thinking, alteration of 
consciousness/mental state); (4) neurological deficits (e.g., weakness, loss of balance, 
change in vision, praxis, paresis/plegia, sensory loss, aphasia) that may or may not be 
transient; or, (5) intracranial lesion. (VA/DoD, 2016, p. 6)  
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Prevalence of Traumatic Brain Injury 
The World Health Organization (2006) classifies TBI as one of the leading causes of 
disease burden worldwide for individuals under 40 years of age. TBI has been associated with 
almost fifty percent of all trauma related fatalities and are two to three times more common in 
males than on females (WHO, 2006).  If the forecasted twofold increase of TBI by 2020 is 
fulfilled, it will become the third leading source of fatality and disability globally (Fernández-
Gajardo et al., 2014). 
Each year around 42 million individuals worldwide suffer a mild TBI (mTBI) (Gardner 
& Yaffe, 2015). In the United States, the number of emergency visits linked to TBIs are 
estimated between 1.7 and 2.2 million per year (Curtis & Epstein, 2014; VA/DoD, 2016; Vakhtin 
et al., 2013), and about 30% of deaths resulting from trauma are connected to TBI (Vakhtin et 
al., 2013). Every year approximately 52,000 deaths are caused by severe TBIs and 80,000 
Americans (Sheriff & Hinson, 2015) join the estimated five million that live with a disability 
after experiencing a TBI (Chauhan, 2014; WHO, 2006).  
Among the civilian population, TBIs are most commonly caused by motor vehicle 
accidents, falls, violence or sport-related injuries (Gardner & Yaffe, 2015; WHO, 2006). Reports 
of TBI prevalence among the military vary, however there is consensus on improvised explosive 
devices (IEDs) as the leading mechanism of injury for head trauma among active service 
members of Operation Iraqi Freedom and Operation Enduring Freedom (IOM, 2011a; VA/DoD, 
2016). Intracranial injuries from IEDs involve a series of mechanical forces (shear stress, 
projectile debris, compression, pressure and tension) starting from the high energy center of the 
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explosion and many variables can impact the severity of the damage (VA/DoD, 2016). 
Researchers are actively working in deciphering the exact mechanisms behind blast-related acute 
structural changes (Goldstein, McKee, & Stanton, 2014). 
Between 2001 and 2011, fatalities of the Iraq/Afghanistan conflicts combined 
documented 42% of casualties that were related to motor-vehicle or air-craft crashes; between 
11-18% were registered as penetrating head injuries from bullets or projectiles from explosive; 
and about 15-20% were blast-related TBI. Thus, 26-38% of all deaths were directly linked to 
brain trauma and the majority were blast-related. Moreover, during 2004-2008, penetrating TBIs 
exceeded the number of closed or blast-related TBIs in a 2:1 ratio, a drastic decline in the 
occurrence of penetrating brain trauma was noted during the following three years (2008-2010), 
with a new 1.3:1 ratio (Chauhan, 2014).  
According to a 2014 CDC report to Congress, between 2000 and 2011 the DoD 
documented 235,046 active duty personnel had a TBI diagnosis among the approximately 5.5 
million Army, Air Force, Navy and Marine Corps service members (VA/DoD, 2016). However, 
prevalence estimates vary, even between different military sources. The CDC and other military 
sources, estimate that between ten to twenty percent of all deployed military members 
(Daneshvar et al., 2015) have suffered a blast-related TBI caused by IEDs (Bryan, 2013; 
Chauhan, 2014; Daneshvar et al., 2015; Gardner & Yaffe, 2015; McKee & Robinson, 2014; 
Twamley et al., 2014; Vakhtin et al., 2013; VA/DoD, 2016), and the majority are classified 
within the range of mild to moderate severity (Daneshvar et al., 2015; Maas et al., 2012; McKee 
& Robinson, 2014; Twamley et al., 2014; VA/DoD, 2016). According to Troyanskaya and 
colleagues (2015), twenty-five percent of combat zone emergency evacuations report injuries to 
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the head and neck and about fifteen percent of those who served in Operation Iraqi Freedom 
recounted having experienced a mTBI (Troyanskaya et al., 2015).  
In 1992, Congress created the Defense and Veterans Brain Injury Center (DVBIC) 
following the recommendations from the Department of Defense (DoD) and the Department of 
Veterans Affairs (VA) on the relevance of TBI as a medical priority for the military. The purpose 
behind the DVBIC was to have a multidisciplinary team serve as a hub for the advancement of 
education and research, and the delivery of patient centered clinical care (IOM, 2011a). 
Improving knowledge on functional impairments following TBIs, the influencing factors that 
may contribute to persistency of symptoms and short- and long-term prognosis are at the top of 
the priorities (VA/DoD, 2016). 
A small recent retrospective study underlined that vitamin D levels lower than 16ng/mL 
were prevalent in patients with a history of TBI, and showed a substantial negative association 
with cognitive test results, regardless of the severity or time since the injury. Those same 
25OHD3 levels were inversely proportionate to the scores of the depression inventory. Overall 
levels were significantly lower than the general population, with 80.2% testing <26ng/mL, of 
which 46.5% were at less than 16ng/mL. These suggest that lower levels are more prevalent 
among post-TBI patients (Jamall et al., 2016). 
Blast-related TBI.  
The role of blast exposure as an etiology for brain trauma (Goldstein, McKee, & Stanton, 
2014) was first reported among World War I infantry soldiers. The force from an explosion can 
generate a wide diversity of injuries compounded together into one (Daneshvar et al., 2015). The 
severity of a blast-related TBI is determined in part by the distance from the initial blast and 
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environmental differences such as exposure while out in the open versus inside of a vehicle and 
whether or not the person had properly secured personal protective equipment. Even low 
intensity recurrent blasts have been documented to cause neuronal tissue alterations (Goldstein, 
McKee, & Stanton, 2014). 
A distinct characteristic of blast injuries is the additive neuronal damage caused by 
multiple forces (VA/DoD, 2016). The strong winds from the blast are traveling at such extreme, 
sustained speeds that can generate a shockwave capable of producing multiple intervals of 
dangerous, drastic contraction and expansion of tissue in fractions of a second. The shockwave 
may cause diffused or focal bleeding and inflammation as the result of shearing and tearing of 
neurovascular and neuronal tissues (Daneshvar et al., 2015). The violent atmospheric pressure 
changes of the blast generate projectile debris elevating the risk of penetrating or blunt injury, or 
both (Chauhan, 2014; VA/DoD, 2016). Lastly, as the body is tossed by the explosion, the brain 
remains susceptible to harm from the displacement of tissue inside the skull from rapid 
acceleration/deceleration and the risk of withstanding additional blunt to the head at landing 
(VA/DoD, 2016). Blast-related TBIs present with a collection of heterogeneous lesions 
representative of the many mechanisms of injury involved (Daneshvar et al., 2015). 
  
TBI Pathophysiology  
Brain tissue is organized into gray matter and white matter. Gray matter functions as the 
central nervous system (CNS) data processor and it is primarily composed by cell bodies and 
unmyelinated axons. White matter composition is predominantly myelinated axons, 
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oligodendrocytes, and other types of glia cells. It is a crucial element of the brain communication 
network, carrying transmission of signals between brain regions (Shi et al., 2015).  
The brain’s proper functions are tied to the cellular and interstitial environments. 
Cytoplasmic and interstitial parameters are maintained by interactions among neuroglia 
(microglia, oligodendrocyte and astrocyte) cells, endothelial cells of the BBB and neurons. 
Membrane proteins and signaling between cells enable adequate supply of oxygen and glucose 
for energy production, support electrolyte transport from general circulation, and facilitate the 
removal of metabolic waste (Chauhan, 2014; Shi et al., 2015).  
  
Figure 1: Endothelial Cells of the BBB, Neuroglia and Neuron.  
Adapted from “Demyelination as a rational therapeutic target for ischemic or traumatic brain injury”  
by H. Shi, X. Hu, R. K. Leak, Y. Shi, C. An, J. Suenaga, J. Chen, & Y. Gao, 2015,  
Experimental Neurology, 272, p. 20. 
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The pathogenesis of TBI begins when an external force disrupts structures and neuronal 
homeostasis. Most TBIs present neurological deficits without or with minimally detectable 
anatomical changes, regardless of the severity. The tissue disruptions arising immediately after 
and as a direct consequence of biomechanical forces may include ischemia, neurovascular 
integrity alterations, and microscopic axonal shearing, and are commonly referred to as the 
primary injury or insult (Chauhan, 2014; Mayer, Huber & Peskind, 2013; VA/DoD, 2016; WHO, 
2006).  
 
Figure 2: Primary injury from TBI.  
(Chauhan, 2014; Daneshvar et al., 2015; Fernández-Gajardo et al., 2014;  
Mayer, Huber & Peskind, 2013; VA/DoD, 2016) 
Co-occurrence of localized and widespread injuries from the same incident is quite 
typical (Chauhan, 2014). Energy transfer from rapid acceleration and deceleration to the skull 
causes brain tissue to shift, compromising cellular membrane and axonal cytoskeleton integrity. 
Mechanical forces cause microscopic neurovascular disruptions that have been linked to the 
clinical symptoms of TBI (Daneshvar et al., 2015; McKee & Robinson, 2014). Oftentimes, 
cellular damage occurs on the primary side of impact and to the opposite side as the brain and 
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skull come to sudden deceleration and the brain hits against surrounding intracranial structures, 
and it may rebound once more causing a secondary hit to the primary site of impact (VA/DoD, 
2016).  
Whether the damage is localized or widespread, the primary injury involves damage at 
the cellular level to neurons, neuroglial and neurovascular tissues (Chauhan, 2014; Fernández-
Gajardo et al., 2014; VA/DoD, 2016), and subsequently initiates various neuropathological 
responses to the mechanical trauma that are classified as secondary injury or insult (Huang et al., 
2015). The secondary multifaceted response includes a series of interrelated and complex 
molecular and cellular reactions involving macrophages, neuroglial cells, inflammatory 
messengers, systemic immune activation, excitotoxicity, disruptions of the blood-brain barrier, 
electrophysiological and ionic disturbances, and neurometabolic interruptions (Chauhan, 2014; 
Mayer, Huber & Peskind, 2013).  
Common concerns during the secondary injury phase include neuroinflammatory 
activities, disruptions of the signal transmission, influx of calcium into cells, metabolic demands 
and abnormal electrophysiology, toxicity from blood-brain barrier leakage and buildup of 
neurotransmitters, intracranial edema and oxidative stress (Chauhan, 2014; Fernández-Gajardo et 
al., 2014; Mayer, Huber & Peskind, 2013; VA/DoD, 2016). Increased energy demands following 
trauma increases intracellular glucose requirements and releases catecholamines to stimulate 
glucose transport which in turn elevate serum glucose concentrations, producing acute 
hyperglycemia. After a TBI, high glucose attracts neutrophils to the wounded region intensifying 
the intracellular alterations, such as acidosis and production of reactive species, worsening of the 
extracellular detrimental environmental conditions including elevation of glutamate. Lastly, it 
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aggravates the inflammation by promoting glia secretion of pro-inflammatory mediators 
(Chauhan, 2014). 
 
Figure 3: Acute hyperglycemia during TBI secondary injury cascade (Chauhan, 2014). 
Adapted from “Traumatic brain injury,” in Neurowiki, 2013, retrieved June 30, 2016,  
from http://neurowiki2013.wikidot.com/individual:traumatic-brain-injury.  
Copyright 2009 by E. Park, J. D. Bell, I. P. Siddiq & A. J. Baker. 
The sums of the cytotoxic and neuroinflammatory processes collectively provoke cellular 
edema, oxidative stress, destruction of the mitochondria and eventually activate neuronal 
apoptosis (Chauhan, 2014). To appreciate the full profile of anatomical responses to the primary 
injury it is important to understand that multiple types of cells are involved in dynamics taking 
place simultaneously inside and outside of the affected cells. The responses are part of built-in 
mechanisms involving up- and down-regulations depending on the stimuli. The activation and 
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progression of inflammatory processes, even with the original purpose of tissue protection may 
exacerbate damage from trauma (Chauhan, 2014; Mayer, Huber & Peskind, 2013), and explains 
the neurological symptoms that develop following a TBI (Fernández-Gajardo et al., 2014). Even 
to this day, the multifaceted biological and structural alterations that occur as a result of a TBI 
are not fully understood (IOM, 2011a; Mayer, Huber & Peskind, 2013; VA/DoD, 2016). The 
following basic biologic mechanisms/steps are focused on processes where vitamin D is 
involved. Appendix B, contains a table of inflammatory mediators categorized by pro- and anti-
inflammation with a brief description of their actions. 
Neuroinflammation, excitotoxicity and oxidative stress. 
Normally, the immune system inflammatory responses are aim at promotion of 
restorative and reparative actions (Fernández-Gajardo et al., 2014). In the central nervous system 
(CNS), inflammatory responses are controlled by CNS-devoted immune cells found in the 
interstitial space and are commonly referred to as neuroglia or glia. Activation of glia cells is 
generally inhibited by healthy neurons. Primary and secondary injuries stimulate concurrent 
release of proinflammatory mediators and elicit glia activation and proliferation (Mayer, Huber 
& Peskind, 2013).  
Under typical conditions, the neuroglia or glia cells, comprised mostly of microglia and 
astrocytes, are immune cells dedicated to survey for pathogenic threats or injury (Mayer, Huber 
& Peskind, 2013). Clusters of activated microglia cells congregate at the site of injury 
immediately after trauma (Chauhan, 2014). Neurotoxic molecules released by the glia following 
activation from TBI are harmful to healthy cells, include reactive oxygen species (ROS), nitric 
oxide (NO), proinflammatory cytokines and chemokines (Huang et al., 2015; Mayer, Huber & 
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Peskind, 2013). Normally, the cell’s built-in antioxidant system is able to keep ROS and NO 
from harmful high concentrations. However, under extraordinary circumstances, when cellular 
functions have been compromised, protective mechanisms struggle to safeguard the cell (Huang 
et al., 2015).  
Neuroinflammation causes neuroglial to become hyperactive, which in turn instigate the 
phosphorylation of mitogen-activated protein kinase (MAPK) pathways. The ultimate goal of 
these pathways is to generate nuclear transcription factors (NTF) to regulate cellular 
inflammation, stress response, cell growth, differentiation and apoptosis (Hur et al., 2014). 
Initiation of the extracellular signal-regulated kinase (ERK), p38-MAPK and Jun-N-terminal 
(JNK) MAPK pathways elicited by activated microglia after brain trauma is responsible for the 
signaling actions to stimulate synthesis of proinflammatory mediators capable of furthering brain 
damage (Fu et al., 2013; Huang et al., 2015). Thus, the disproportionate or extended activation of 
microglia following traumatic injury may exacerbate neuronal damage by maintaining a cycle of 
glia activation and neuronal injury progression (Huang et al., 2015).   
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Table 1: Mitogen-activated protein kinase (MAPK) pathways 
Extracellula
r stimuli 
Cell 
membrane 
Cytoplasm 
MAPK 
NTF 
Gene stimulation: protein 
synthesis affects 
1. ischemia,  
2. toxicity,  
3. inflammatory 
cytokines 
4. hormones/ 
growth 
factors 
5. mechanical 
trauma 
(TBI) 
Activation 
of 
N-methyl 
D-aspartate 
(NMDA) 
glutamate 
receptor  
Following NMDA 
receptor activation:  
• initiation of 
several 
phosphorylation 
steps produce a 
nuclear membrane 
transcriptor factor 
(NTF) 
• major 
extracellular 
glutamate efflux 
ERK 
MAPK 
Initiates 
apoptosis and 
shuts down the 
cell’s survival 
mechanisms 
Are involved 
in nitric oxide 
accumulation, 
reactive 
oxygen 
species 
production, 
and increases 
of pro-
inflammatory 
cytokines/ 
chemokines.  
P38 
MAPK 
Promotes 
neuroinflamma
-tion 
JNK 
MAPK 
Promotes 
neuroinflamma-
tion 
 cell membrane & nuclear membrane 
Astrocytes are advantageously located between the neurovascular and neuronal cells with 
the purpose of regulating essential interactions concerning the BBB. Neurons rely on them for 
almost all of their cellular functions, counting on astrocytes to regulate concentrations of 
neurotransmitters, mediate synapsis and preserve ionic balances. It should not be a surprise that 
they outnumber any other type of cell in the brain. After head trauma, their activation can be 
triggered by damaged neurons or microglia activation. Activated astrocytes are beneficial in 
isolating injured neurons by substrate deposition after a traumatic event. However, this barrier 
also impedes axonal communication and restoration. They are also vulnerable to structural 
damage themselves, not only unable to support neuronal homeostasis, but releasing 
inflammatory mediators as well (Mayer, Huber & Peskind, 2013). 
Oligodendrocytes’ responsibilities include making, maintaining and regenerating the 
myelin sheath supporting the neuronal axons actions and integrity. However, they are 
particularly vulnerable due to a low capacity to fight the oxidative stress that follows head 
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trauma. The unmet demand of energy following acute trauma can reduce the cell’s ability to 
perform its functions and lead to permanent loss of the myelin. Demyelination contributes to 
neuronal transmission alterations and cause neurological symptoms after TBI. Therapeutic 
approaches targeting oxidation and mitochondrial dysfunction could prevent or ameliorate 
axonal demyelination (Shi et al., 2015). 
As neuroinflammation continues, Schwann cells become activated as well and contribute 
to the transmission dysfunctions of the wounded axons (Mayer, Huber & Peskind, 2013). 
Intracellular edema along with ionic and metabolic changes, eventually lead to further structural 
damage of the axons and infiltration of macrophages (Chauhan, 2014). 
Excessive or persistent inflammatory response has been considered as a possible 
explanation for neurological deficits following a TBI (Mayer, Huber & Peskind, 2013). Multiple 
autopsy studies of individuals with mTBI found abnormal tissue structures correlated with 
neuroinflammation. Findings supporting inflammation included signs of axonal injury such as 
demyelination, varicosities, axonal bulbs at site of detachment and Wallerian degeneration, and 
clusters of activated microglia and macrophages containing degenerated myelin have also been 
found in the same area. All these alterations can be expected closely after trauma, except that 
these findings were observed up to 18 years post-TBI, in additions to thinning of neuronal tracts 
(Mayer, Huber & Peskind, 2013). Finding ways to mitigate, prevent or stop the overactive glia 
has been identified as a potential treatment target for TBI (Huang et al., 2015). 
Neuroinflammation is intimately related to oxidative stress and excitotoxicity as 
originators and promoters of cellular damage. Their combined actions can consequently elicit 
cell necrosis, apoptosis and autophagy. Oxidation damage can initiate multiple pathways to 
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regulate cell death. Mitochondrial lysis is another known way to trigger apoptosis. Signs of 
apoptosis in autopsies of TBI patients have been observed up to a year after the original 
mechanical trauma. Autophagy initiated during ischemia/reperfusion, hypoxic stress or post-TBI 
is mostly driven by oxidative stress. Laboratory and clinical findings have identified a genetic 
pathway promoting autophagy after TBI (Fernández-Gajardo et al., 2014).  
Oxidative stress from reactive oxygen and nitrogen species is known to occur in the brain 
after TBI and the antioxidant actions directly rely on the BBB to attain the best possible effects. 
Damage is subsequent to the discrepancies between high concentrations of reactive species and 
the cell’s overwhelmed antioxidant mechanisms. Because of low antioxidant capacity, high 
demand for oxygen and high amounts of iron, neurons are particularly susceptible to elevation of 
reactive oxygen species (ROS) and reactive nitrogen species (NOS) following brain trauma 
(Fernández-Gajardo et al., 2014). 
ROS contributions to intracellular damage are excitotoxicity, calcium influx, intracellular 
edema and metabolic collapse. ROS also facilitates structural weakening and disruption of the 
neurovascular vessel walls, thus increasing the permeability of the blood-brain barrier (BBB). 
Cell damage from oxidation causes declines in brain-derived neurotropic factors consequently 
worsening cognitive decline and neuronal communication (Fernández-Gajardo et al., 2014).  
At the beginning of the secondary injury phase, a sudden neuronal membrane 
depolarization precedes the colossal release of the neurotransmitter glutamate. Glutamate efflux 
surpasses the reuptake ability of astrocytes (Charier et al., 2015). Excitotoxicity from glutamate 
triggers harmful influx of calcium ions, which precedes a series of neurotoxic events within the 
cell, augmenting cell edema and production of NOS. Glutamate toxicity harms the affected cells 
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as well as neighboring cells and creates a risk for apoptosis on all glutamate-stressed cells 
(Fernández-Gajardo et al., 2014).  
Temporary increases of amyloid β and its precursor protein in the axons takes place 
following a TBI (Daneshvar et al., 2014). Studies showed that multiplied levels of amyloid β 
promote low-voltage calcium channel expression and suppressed the vitamin D receptor (Gezen-
Ak, Dursun & Yilmazer, 2013). 
 
Figure 4: Inflammatory mediator, oxidative stress and excitotoxicity.  
Adapted from “Traumatic brain injury,” in Neurowiki, 2013, retrieved June 30, 2016, from 
http://neurowiki2013.wikidot.com/individual:traumatic-brain-injury. Copyright 2009 by E. Park, J. D. Bell, 
I. P. Siddiq & A. J. Baker. 
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Diffuse axonal injury. 
Neurovascular vessels and axons are particularly susceptible to damage from rapid brain 
shifting because of their elongated structures (Daneshvar et al., 2015; McKee & Robinson, 
2014). Diffuse axonal injury (DAI) or traumatic axonal injury (TAI) is seen in all types of TBIs, 
thus it is considered the signature injury of TBI (Daneshvar et al., 2015).  
DAI is a dynamic process characterized by widespread microscopic injuries, that unfolds 
over time as a result of mechanical interruptions and membrane perforation to white matter tracts 
or axons. Compromised membrane integrity allows drastic influx of calcium while driving 
potassium out of the cell (Chauhan, 2014; Daneshvar et al., 2015; McKee & Robinson, 2014). 
Calcium influx stimulates sodium-calcium (Na+/Ca++) pumps and sets in motion regulatory 
actions of calcium-dependent enzymes to catabolized damaged proteins. The sudden increase of 
intracellular calcium leads to mitochondrial membrane leakage and axonal energy production 
collapses (Chauhan, 2014). Mitochondrial energy breakdown is a known predictor for poor 
outcomes (Fernández-Gajardo et al., 2014). Meanwhile, the Na+/Ca++ pumps continue to 
exacerbate the burden on the axon cytoskeletal structures and the mitochondria by importing 
more calcium ions into the cell. Finally, the process of axonal degeneration culminates with 
necrosis and apoptosis (Chauhan, 2014).  
Cellular changes that arise from the stretching and tearing of axons begin minutes to 
hours following the primary insult. Ramifications of the intracellular calcium overload include 
damage to the transmission structure on the cell and impaired transport. The large amount of ion 
transport proteins along the nodes of Ranvier makes this area particularly susceptible to 
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deterioration from calcium influx and membrane disturbances (Chauhan, 2014; Daneshvar et al., 
2015).  
Continuation of calcium import, with impaired ionic and neurotransmitters transport and 
intermittent areas of inflammation along the axon stimulate the formation of axonal varicosities 
and lead to further structural degeneration and deformations. Axonal varicosities are 
concentrated areas of inflammation considered weakened structural points along axonal 
cytoskeleton. Within minutes to hours after trauma, localized swelling and the buildup of un-
transported molecules lead to severed axons from the body of the neuron and creates axonal 
bulbs at the detached ends of the axon, at the breaking point, usually at the level of the nodes of 
Ranvier (Chauhan, 2014). 
As the axonal ends separate from the cell bodies, communication between different 
regions of the brain cease and Wallerian degeneration is initiated. Wallerian degeneration is a 
process in which the distal portion of a nerve fiber that has either been detached or damaged 
begins to degenerate. Using a DAI experiment model, detection of DAI occurred fifteen minutes 
after the injury. Axonal detachment was prevalent at thirty minutes and was followed by 
Wallerian degeneration beginning two to three hours after trauma (Chauhan, 2014).  
Compromised myelin sheath renders transmission of action potential down the axon 
inoperable, impairs the cells energy sources and makes the unprotected axon more vulnerable to 
degradation (Shi et al., 2015). Acute deterioration of the myelin sheath exposes the axon 
facilitating infiltration of macrophages and Schwann cells. The progression of axonal 
demyelination is believed to continue years after the original trauma and may be the source for 
persistent symptoms and the effects of neuronal degeneration later in life (Chauhan, 2014). 
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Blood-brain barrier disruption. 
The BBB can be described as an adaptable interface that is capable of restricting access 
to damaging substances from the circulatory system, while allowing crossing of necessary 
nutrients and substances to sustain the ideal conditions for proper neuronal function. Normally, 
neurovascular modifications that mediate these interactions occur from the influence of 
astrocytes on endothelial cells (Mayer, Huber & Peskind, 2013).  
Regulation of the endothelial tight junctions is an extremely important protective 
mechanism for the brain since components of blood, plasma and peripheral leukocytes are toxic 
to brain cells. Structural alterations to microvascularity from mechanical forces, damage to 
astrocytes (Daneshvar et al., 2015; Mayer, Huber & Peskind, 2013), hypoxic death of endothelial 
cells, or oxidative damage to tight junction protein structures (Won et al., 2015) may lead to 
increased BBB permeability. Despite of the etiology, all TBIs whether from open or closed 
trauma, will compromise brain microvascular cells of the BBB. Consequently, the neurotoxicity 
caused by blood exposure exerting a pro-inflammatory action will increase activated glia and 
leakage of BBB (Chauhan, 2014; Mayer, Huber & Peskind, 2013). 
Infiltration of peripheral leukocytes join in with other brain immune defenses, and 
lamentably, promote oxidative stress by increased production of nitric oxide (NO). The NO 
interactions on the microglia membranes foster additional ROS synthesis and suppress enzymatic 
activity necessary for the production of adenosine triphosphate (ATP) (Fernández-Gajardo et al., 
2014). 
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Figure 5: Secondary injury from BBB breakdown.  
Adapted from “Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body 
Inflammation in Bipolar Disorder?,” Scientific figure on ResearchGate, n.d., Retrieved June 30, 2016, from: 
https://www.researchgate.net/277352521_fig1_Proposed-model-of-blood-brain-barrier-BBB-disruption-in-
bipolar-disorder-Increased-BBB. 
Large amounts of uncoagulated blood coming into contact with brain cells, as seen with 
hematomas can cause severe brain edema and increased ICP. Edema and inflammation 
compromised brain functions even further and require immediate medical interventions to 
protect the brain cells (Chauhan, 2014). The infiltration of systemic leukocytes into the brain 
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interstitial space prompts additional recruitment of glia and peripheral immune cells resulting in 
a systemic immune reaction (Mayer, Huber & Peskind, 2013).  
In summary, the pathological cascade triggered by different degrees of axonal and 
neurovascular structural alterations is not tied to a single, isolated timed-event. Evidence 
demonstrates that TBI damage is progressive in nature, with interlayering and complex 
anatomical responses and may persist over a span of months, years or even decades. 
Understanding the mechanisms triggering the secondary responses is crucial in order to develop 
therapies to prevent or attenuate their impact.  
 
Overview of TBI Clinical Management  
Clinical management of TBI can be cumbersome, in part because of the progressive 
nature of the disorder and complexities surrounding the wide variety of clinical signs. According 
to the IOM (2011a), approaches aiming at one specific aspect of the pathological alteration post-
TBI have not yet succeeded and standardization of a particular consistent or effective protocol 
for TBI management has not been achieved (IOM, 2011a).  
The use of imaging studies and laboratory results for conclusive diagnosis, guidance of 
clinical care or as prognosis predictors is not recommended (VA/DoD, 2016; WHO, 2006). 
Timely recognition of TBI symptoms enables early clinical management, improves outcomes 
and prevents undesirable consequences (WHO, 2006). It is important to underline that there is no 
definite correlation between the documented degree of severity of TBI and patient prognosis 
(Maas et al., 2012; Stein, 2015).   
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The unpredictability of physiological responses seen with TBI is related to the distinctive 
characteristics of the person at the time of the incident, amount and direction of the forces, and 
environmental factors. Other factors likely to modify the body’s response may involve genetic 
makeup, a prior diagnosis of TBI, overall health, nutritional and hydration status preceding the 
incident, lack of sleep and high concentrations of stress hormones (VA/DoD, 2016). 
 
Symptomology and Manifestations of Mild TBI 
Given that the majority of reported TBIs are considered mild in severity (Gardner & 
Yaffe, 2015; Maas et al., 2012; Mayer, Huber & Peskind, 2013; McKee & Robinson, 2014; 
Stein, 2015; Twamley et al., 2014; VA/DoD, 2016), this section will focus on this data. It has 
been proposed that microscopic structural lesions correspond to milder post-injury symptoms 
(Daneshvar et al., 2015). However, the prevalence and severity of some symptoms have been 
found to be higher in mTBIs than in more severe cases, as it is the case with post-traumatic 
headaches (Mayer, Huber & Peskind, 2013). This seems to contradict the notion that the severity 
of structural damage usually corresponds to the severity of the TBI.  
Although the magnitude of structural damage may be narrower for an mTBI, the 
metabolic and neuronal disruptions are thought to result from the aftermath of metabolic, ionic 
and physiologic alterations rather than the structural changes. The pathological profile created by 
the timing and magnitude of these anatomical responses has been known to progress into chronic 
neurodegeneration in a subgroup of the population (VA/DoD, 2016).  
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Figure 6: DoD TBI Diagnoses from 2002-2009.  
Reprinted from “Clinical practice guideline for the management of concussion-mild traumatic  
brain injury (version 2.0),” by VA/DoD, 2016, p. 101, Retrieved June 19, 2016, from 
www.healthquality.va.gov/guidelines/Rehab/mtbi/.  
Mild TBIs are characterized by lack of obvious anatomical trauma, the acute neurological 
deficits tend to be categorized as mild and frequently resolve on their own in a matter of few 
days or weeks (McKee & Robinson, 2014; WHO, 2006). However, about 10-15% of people will 
be diagnosed with postconcussive syndrome, a condition characterized by persistency of TBI-
associated symptoms (McKee & Robinson, 2014). The invisible manifestations of a single or 
multiple close-head TBIs are often insidious and may take years to appear, though they may be 
traced back to the initial injury (Daneshvar et al., 2015; IOM, 2011a). 
During the initial assessment of mTBI patients may present with a combination of 
physiological, cognitive and neuropsychological symptoms. Figure 7 contains the list of 
symptoms highlighted in the VA/DoD mTBI practice guidelines that may indicate the need for a 
neurological consult (VA/DoD, 2016). 
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Figure 7: Initial presentation: Indicators for immediate referral.  
Reprinted from “Clinical practice guideline for the management of concussion-mild traumatic  
brain injury (version 2.0),” by VA/DoD, 2016, p. 17, Retrieved June 19, 2016, from 
www.healthquality.va.gov/guidelines/Rehab/mtbi/.  
Some commonly reported physiological symptoms are headaches, dizziness, nausea, 
fatigue, sleep disturbances, and seizures (Chauhan, 2014). Roughly 30-90% of patients complain 
of post-traumatic headaches (VA/DoD, 2016) and around 24-74% of dizziness, both symptoms 
resolving within three months following an mTBI. Fatigue has been reported in about 73% of 
TBI patients and has been linked to lower levels of social interaction and isolation. Sleep 
disorders develop in about 30-73% of individuals diagnosed with TBI. Many of these symptoms 
exist side by side and may contribute to neuropsychological or cognitive deficits. Researchers 
found that improving sleep problems that developed after a TBI reduce the incidence of 
psychological impairments (Chauhan, 2014).  
At least one psychosomatic behavioral alteration has been reported for nearly all TBI 
patients, involving the onset of depression, anxiety, or mood changes.  Reports of post-TBI 
cognitive symptoms include difficulties with concentration, attention, decreased processing 
speed, impaired memory, judgement and problems with planning and multitasking (VA/DoD, 
2016).  
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Figure 8: List of possible mTBI symptoms from the VA/DoD algorithm for the management of mTBI.  
Reprinted from “Clinical practice guideline for the management of concussion-mild traumatic  
brain injury (version 2.0),” by VA/DoD, 2016, p. 17, Retrieved June 19, 2016, from 
www.healthquality.va.gov/guidelines/Rehab/mtbi/.  
Many of the symptoms reported by combat veterans recovering from TBI include 
cognitive dysfunctions such as problems with concentration, memory impairment and executive 
function irregularities (Daneshvar et al., 2015; Twamley et al., 2014). These deficiencies in 
executive functions diminish a person’s ability to plan and organize their day, to manage their 
time, or even completely quench their inability to multitask. Studies have indicated that cognitive 
functionality can directly influence employability (Twamley et al., 2014). Thus, this shows that 
special attention should be paid at resources available to ensure combat veterans can return to 
their family and community with the highest level of reintegration and adaptability possible.  
 
TBI Outcomes 
TBI survival rates among combat-related wounded soldiers have increased significantly, 
in part due to modern advances in personal protective armour (Vakhtin et al., 2013) and 
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improved military medical interventions (Johannigman et al., 2015). Consequently, many 
veterans are coming back home or being returned to active duty after surviving their injuries.   
Holistic, patient-oriented TBI management aims at improving symptoms, quality of life 
and functionality levels (VA/DoD, 2016). Most combat-related TBIs are considered mild in 
nature (Daneshvar et al., 2015; Maas et al., 2012; McKee & Robinson, 2014; Twamley et al., 
2014; VA/DoD, 2016) and, although mortality rate is low, long-term disability is common 
(Curtis & Epstein, 2014; WHO, 2006). Curtis and Epstein (2014) state that as many as 20% of 
patients with a mild TBI will go on to experience chronic symptoms related to postconcussive 
syndrome (Curtis & Epstein, 2014), other estimates are as high as 30% (Vakhtin et al., 2013).  
Disability levels vary among veterans who have suffered one or more TBI and 
rehabilitation outcome predictions are difficult. Severity of symptoms has been directly 
associated with the degree of disability, poorer degree of functionality, lower reintegration in the 
community and employability. Cognitive deficiencies contribute to learning difficulties that 
decrease their ability to learn new skills or earn a new degree (Twamley et al., 2014).  
An estimated 7% of Iraq and Afghanistan combat veterans receiving health care at VA 
facilities continue to experience post-TBI symptoms related to cognitive deficits, sleep 
difficulties, chronic fatigue, emotional problems and post-concussive headaches (Twamley et al., 
2014). However, it is unclear how the high frequency of neuropsychiatric comorbidities may 
contribute to cognitive impairments (Troyanskaya et al., 2015; Twamley et al., 2014).  
A small sample, not-blinded pilot study, found that twelve-weeks of cognitive 
rehabilitation that included restorative and compensatory approaches could improve post-
traumatic cognitive deficits and prospective memory in combat veterans with history of TBI, 
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even with PTSD as comorbidity (Twamley et al., 2014). Other studies have found a direct 
correlation between differences on the timing and quality of clinical care and rehabilitation 
programs with the overall outcomes (Maas et al., 2012; Stein, 2015). It is sensible to conclude 
that further examination of rehabilitation strategies may offer potential gains in service members’ 
rehabilitation outcomes.  
Classification disparities among facilities and practitioners (Gardner & Yaffe, 2015) and 
widespread treatment differences could explain some of the differences in outcomes (Maas et al., 
2012). Additional challenges concerning therapeutic effectiveness are embedded in an 
unpredictable collection of physiological and environmental conditions. Genetic susceptibility, 
preinjury psychosocial wellbeing as well as post-injury factors influencing psychosocial health, 
pre-existing illness, the mechanism of trauma, as well as the quality and time of clinical care can 
arbitrarily and collectively affect therapeutic outcomes. The need to expand understanding of the 
multidimensionality of phenotypical expressions among comparable injuries is of utmost 
significance (Maas et al., 2012; VA/DoD, 2016). Thus far, thirty-two transcription factors have 
been related to genetic up-regulation following ischemic injury and are suspected to be involved 
in inflammatory responses in rat brain cells (Ridder et al., 2009).  
TBI is known to present with acute and chronic alterations of neuronal functions 
(Daneshvar et al., 2015; Vakhtin et al., 2013). Multiple long-term complications that patients 
with a history of TBI may face include reduction of life expectancy (Chauhan, 2014) and an 
increased risk for developing neurodegenerative diseases later in life (Chauhan, 2014; Daneshvar 
et al., 2015; Gardner & Yaffe, 2015). 
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The body of evidence suggests that an isolated TBI may result in gray and white matter 
degeneration and can trigger or speed up age-associated neuronal deterioration. It also increases 
the likelihood of developing progressive neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s. Postmortem brain examinations of combat veterans with a positive history of blast-
related mTBI due to IEDs, showed evidence of tau neurofibrillary accumulation, chronic 
traumatic encephalopathy (CTE), axonal and microvascular tissue damage, signs of proliferation 
of astrocytes and microglial activation nearby lesions. The autopsies revealed initial signs of 
CTE in four out of five of the deceased combat veterans that overlapped with a diagnosis of post-
traumatic stress disorder (PTSD) in life, implying a possible connection between the pathology 
of both conditions (Daneshvar et al., 2015). 
A greater understanding of the immediate and lifelong consequences that mTBI has on 
functioning still remains a priority for research. Moving forward, it is important for researchers 
and clinicians to consider preventive, treatment and restorative strategies that can minimize the 
disease burden among past, current and future military service members. Unemployment and 
cognitive difficulties often co-exist. Reintegration programs for combat veterans dealing with 
persistent neurological deficits of mTBIs and their families could provide resources and 
cognitive training to support their transitions and improve their successful reintegration to the 
community.  
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CHAPTER 4: VITAMIN D BACKGROUND 
Discovered in the early 20th century, vitamin D’s clinical relevance did not become 
apparent until the connection of its extreme deficiency was identified as the leading cause of 
rickets. First described in the mid-1600s, the clinical signs of rickets are visibly detectable as 
bone deformities, growth delays and weakening of the muscles which were eventually seen as 
being due to extreme hypovitaminosis D (Holick, 2006). Early experiments provided the data 
needed to understand how rickets could be prevented by increasing sun exposure and vitamin D 
dietary intake. In the early 20th century scientists were finally able to appreciate the 
improvements on bone mineralization from this intervention, especially on the epiphyses of long 
bones, by examining children’s x-rays (Holick, 2006; Eyles, Burne & McGrath, 2013).  
The high prevalence of rickets, led the U.S. government to adopt the fortification of milk 
with the fat-soluble nutrient as part of public health policy program for the prevention of rickets. 
In 1928, the discovery of vitamin D’s chemical structure by Adolf Windausin (Eyles, Burne & 
McGrath, 2013), facilitated new improvements for food fortification techniques (Holick, 2006). 
The success of the policy became evident by the marked reduction of rickets cases in the mid-
1900s, almost eradicating the disease (Holick, 2006; Looker, Dawson-Hughes, Calvo, Gunter, & 
Sahyoun, 2002; Rovner & O’Brien, 2008).  
 
Vitamin D Photosynthesis 
Photosynthesis.  
Vitamin D is a fat soluble molecule that undergoes a complex process from initial 
synthesis to activation before it can exert hormonal effects. Throughout a series of biochemical 
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reactions, vitamin D exists in several different forms and goes by many different names 
depending on the molecular structure. During the early stages of food fortification, the two 
different forms of vitamin D were identified and classified as D2 or egocalciferol, which is found 
in plants, and D3 or cholecalciferol, which is produced by animals. Fortification of food and oral 
supplements use either form (Eyles, Burne, & McGrath, 2013; Holick, 2007; Holick et al., 2011).  
In animals, the metabolic process of vitamin D3 begins when 7-dehydrocholesterol, 
commonly known as “cholesterol,” an inert molecule on the epidermis layer of skin, is exposed 
to the solar ultraviolet-B (UVB) radiation giving rise to cholecalciferol, the inactive form of 
vitamin D3. The inactive molecule of vitamin D3 is transported in the circulatory system by 
transport proteins to the liver where several P450 enzymes attach the first hydroxyl group in a 
process known as hydroxylation. The newly formed 25-hydroxyvitamin D3 (25OHD3) or 
calcidiol has a lifespan between two to three weeks, thus making it the ideal biological marker to 
screen and monitor levels (Annweiler et al., 2014; Holick, 2007; Holick et al., 2011; Jamall et 
al., 2016; Wang, Ji, Tong & Zhang, 2014; Wentz et al., 2014). 25OHD3 undergoes a second 
hydroxylation in the kidneys from which the activated 1,25-dihydroxyvitamin D3 or 1,25OH2D3 
emerges ready to function as a hormone (Eyles, Burne, & McGrath, 2013; Holick, 2006; Holick, 
2007). 
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Figure 9: Photosynthesis steps of vitamin D.  
Adapted from “Vitamin D deficiency,” by M. F. Holick, 2007,  
In The New England Journal of Medicine, 357(3), p. 269.  
Vitamin D synthesized by sun exposure has been found to last twice as long in circulation 
when compared to the orally ingested form. The skin is an extremely efficient source of vitamin 
D. An estimated 1,000–1,500 hours out in the sun during the spring, summer and fall should 
provide enough vitamin D for the majority of humans to cover for the winter months. One dose 
of UVB irradiation, defined as the exposure needed by an adult dressed with a swimsuit to have 
superficial pink tone 24 hours later, can generate the equivalent of 10,000-25,000 IU of oral 
intake (Holick et al., 2011). Rovner & O’Brien (2008) stated that adequate synthesis of fair skin 
individuals would require UVB radiation exposure for about 5 to 15 minutes between the hours 
of 10 am and 3 pm during the abovementioned seasons. However, individuals with darker skin 
may need five to ten times longer UVB exposure length for an equivalent production (Rovner & 
O’Brien, 2008).  
Factors influencing photosynthesis. 
Vitamin D is a unique nutrient; although humans can ingest it from food sources, 
including oral supplements, human skin is perfectly capable of synthesizing this nutrient to 
adequate levels with appropriate exposure to sunlight. However, scientists have identified factors 
that influence the body’s ability to produce vitamin D. Non-modifiable factors known to reduce a 
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person’s ability to photosynthesize vitamin D include dark skin tone, age (decline of 7-
dehydrocholesterol), weather (cloud coverage and smog), cold seasons (shorter duration of sun 
light) and latitude (higher than ~40°). On the other hand, adjustments to certain behaviors (length 
of time spent outside, frequency and duration of exposure to UVB), type of clothing (degree of 
skin coverage), dietary choices and supplementation that could potentially counteract the impact 
of non-modifiable elements (Groves, McGrath & Burne, 2014; Harms, Burne, Eyles, & 
McGrath, 2011; Holick, 2006; Holick, 2007; Looker et al., 2002; Rovner & O’Brien, 2008).  
Individuals with dark skin tone require longer UVB exposure for adequate metabolism of 
vitamin D3 due to higher concentration of melanin on their skin (Harms et al., 2011; Holick, 
2007; Jamall et al., 2016). A decline in 7-dehydrocholesterol content in the skin is an expected 
change observed with aging, thus the decrease of the molecular precursor for cholecalciferol 
results in decreased synthesis (Holick, 2007). It has been reported that decreased intensity of 
UVB radiation during the winter months accounts for the seasonal differences of vitamin D 
photosynthesis, being especially significant in latitudes greater than ~40° (Holick, 2006; Holick, 
2007; Looker et al., 2002). The photochemical smog of urban areas keeps sunlight from reaching 
past it and might explain the higher occurrence of hypovitaminosis D when compared to rural 
populations (Holick, 2007). Clothing and the application of sunscreen are known to decrease 
skin exposure to UVB radiation thus reducing production of vitamin D (Eyles, Burne & 
McGrath, 2013; Holick, 2006; Holick, 2007; Jamall et al., 2016). 
Studies have found that certain medical conditions and medications increase the risk of 
hypovitaminosis D. Sequestration of vitamin D in excess fatty tissue reduces the vitamin D 
reaching circulation in obese individuals. In cases of liver and kidney insufficiency and failure, 
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organ damage results in metabolic disruption of active vitamin D. Skin grafts or extensive burn 
scarring deprive skin from its synthesis abilities (Holick, 2007). Medications for the treatment of 
epilepsy and HIV/AIDS promote destruction of 25OHD3 and 1,25OH2D3 (Holick, 2007; Holick 
et al., 2011). 
Testing for hypovitaminosis D. 
The Institute of Medicine (IOM) and The Endocrine Society (TES) concluded that the 
evidence did not support regular screening of vitamin D levels except for individuals that are 
considered to be at risk for deficiency (IOM, 2011b; Holick et al., 2011). It is important during 
health assessments, to performed a thorough history intake that include questions on past medical 
diagnosis, current medications, family history and certain behaviors, as the answers could guide 
clinical judgement.  
The Endocrine Society (2011) indicated screening when confirmed pathology of liver, 
kidney or gastric systems is present and with metabolic and endocrine conditions known to alter 
the metabolism of vitamin D (Holick et al., 2011). Clinicians should screen for deficiencies those 
(1) with a body mass index above 30, (2) taking antiepileptic, antiretroviral, glucocorticoids, and 
cholestyramine medications, (3) diagnosed with a malabsorption condition or (4) food allergies, 
(5) renal or hepatic insufficiencies, (6) advanced age, or (7) primary hyperparathyroidism 
(Holick, 2007; Holick et al., 2011). Screening is also important in persons with altered skin 
functions, as seen with extensive scaring (Holick, 2007; Holick et al., 2011).  
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Vitamin D Deficiency versus Insufficiency 
At the time of this review, there is still no agreement concerning the assay criteria for 
deficiency and insufficiency. According to Looker and colleagues (2002), deficiency occurs 
when the levels of circulating 25OHD3 present with positive clinical symptoms of bone 
demineralization, secondary hyperparathyroidism, or other signs of poor bone health. 
Insufficiency, sometimes called subclinical deficiency occurs when levels are above deficiency 
but low enough to contribute to bone disease (Looker et al., 2002) and other pathologies (Holick, 
2007; Holick et al., 2011). 
The medical community has struggled to reach the consensus necessary to identify 
clinical guidelines for assessing, monitoring, and correcting vitamin D deficiencies (Eyles, Burne 
& McGrath, 2013; Looker et al., 2002; Rovner & O’Brien, 2008; Wentz et al., 2014). The IOM 
and TES do not concur on their clinical reference values or recommendations. In 2011, these two 
major organizations published their own set of clinical guidelines for the screening, classification 
and optimization practices (refer to table 2 for reference values) (Holick et al., 2011; IOM, 
2011b).  
Table 2: 2011 Vitamin D reference values from the IOM and TES. 
 IOM, 2011b Holick et al., 2011 
Sufficiency >20ng/mL (>50nmol/L) 30 - 100 ng/mL (75 - 250nmol/L) 
Insufficiency   21 - 29 ng/mL (52 - 72nmol/L) 
Deficiency <20ng/mL (<50nmol/L) <20 ng/mL (<50nmol/L) 
 
The significant relationship between vitamin D and the musculoskeletal system has been 
established and accepted within the scientific community, and the mechanisms involved have 
been extensively studied. The IOM indicated that their committee of experts appraised the newer 
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scientific evidence available since publishing their previous clinical practice guidelines in 1997 
and did not find the data to be supportive of any health benefits beyond bone health. Thus, the 
supplementation recommendation were designed to support optimal bone health based on the 
minimum 25OHD3 levels necessary to support the musculoskeletal system. The institute’s 2011 
update significantly increased the threshold for deficiency from 10ng/mL or 25nmol/L in 1997, 
to 20ng/mL or 50nmol/L. It is important to underline in both occasions the guidelines were based 
solely on bone homeostasis (IOM, 2011b).  
The IOM set the adult vitamin D daily requirements to 400 IU (international units), with 
a dietary allowance of 600 IU and a total upper limit of 4,000 IU. Referencing the data from the 
NHANESIII survey, which showed daily dietary intake below standard requirements, the 
committee deduced that adequate solar exposure may explain why average levels were higher 
than 20ng/mL, which satisfies the cutoff proposed by the IOM. The committee raised concerns 
about possible public misperceptions regarding vitamin D, driving a trend for increased 
screenings and warns that inconsistencies on the cut-offs used between laboratories, which may 
mislabel a person as deficient (IOM, 2011b). 
In summary, the IOM’s dietary recommendations were established to keep a 
concentration of at least 20ng/mL. The committee counsels against surpassing the daily upper 
limit of 4,000 IU and warns that higher intake could come with detrimental risks to health and 
that the likelihood of excessive intake is heightened by the availability of fortified foods and an 
increased intake of supplements frequent in North America. The committee concludes that 
additional research is needed in order to expand the health benefits of vitamin D (IOM, 2011b). 
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In contrast with the IOM recommendations, after review of the available literature, The 
Endocrine Society (TES) set forth guidelines which suggest vitamin D levels should be higher in 
order to maintain health. The TES taskforce established the threshold for deficiency at 20ng/mL 
or 50nmol/L, aligning with the IOM parameter. However, they also defined the range between 
21-29 ng/mL as insufficiency, and determined the sufficiency range to be at of 30-100 ng/mL. 
The insufficiency range was set just below the demonstrated ideal threshold in which parathyroid 
hormone levels and adequate intestinal calcium absorption are believed to be optimally balanced. 
When compared with the IOM report, the TES asserts that vitamin D deficiency is common in all 
age groups and that few foods contain vitamin D, and recommends supplementation based on 
age group and clinical presentation (Holick et al., 2011). 
The TES taskforce indicated that optimization of vitamin D deficiency in adults can be 
achieved by administering either D2 (egocalciferol) or D3 (cholecalciferol). They suggest that 
healthy adults age 19 to 70 need at least 600 IU daily in order to maximize bone health and 
muscle function, but clarified that 600 IU may not be enough to increase vitamin D levels above 
30ng/mL consistently or to support other non-skeletal benefits. The daily requirement was set 
between 1,500 and 2,000 IU for all adults in order to maintain 25OHD3 blood levels greater than 
30ng/mL. In deficient adults older than 19 years of age initial supplementation involves 50,000 
IU/week or 6,000 IU/day for two months to correct the deficiency, followed by the maintenance 
dose of 1,500 to 2,000 IU a day (Holick et al., 2011).  
The TES guidelines set a tolerable upper limit (UL) at 4000 IU/day for children between 
1 and 8 years of age and 10,000 IU/day for anyone older than 9 years old, except for pregnant or 
lactating teens, for which the 4,000 IU/day continues to apply. The committee decision to set the 
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UL to 10,000 IU/day was based on a study in which men were supplemented with this dose for 5 
months without reports of increase blood calcium concentrations or renal calcium excretion 
(Holick et al., 2011). 
Although the IOM committee warned that levels above 50ng/mL may be associated with 
higher mortality, the TES did not support this claim and stated the evidence does not support any 
disadvantages of increased intake, except for cases of lymphoma or chronic granuloma-forming 
disorders (such as tuberculosis and sarcoidosis). The TES stated that an upper threshold to 
prevent vitamin D toxicity has not been identified and the IOM UL recommendations were based 
on observations from the 1940s. TES referenced studies in adults and children that showed 
negative health concerns with 25OHD3 blood levels of 150ng/mL or above. For this reason they 
believed an UL of 100ng/mL offers a safe parameter to prevent the risk of developing 
hypercalcemia or hypercalciuria (increased calcium renal excretion) (Holick et al., 2011).  
The TES does agree with the IOM in the desirability for better and more reliable assay to 
measure vitamin D serum levels. Their report concludes and suggests that additional, high-
quality studies on vitamin D replacement and non-skeletal benefits are warranted in order to 
solidify the evidence and develop stronger recommendations (Holick et al., 2011). 
 
Prevalence of Low Vitamin D 
Cases of extreme, chronic hypovitaminosis D (the type that leads to rickets) are rare in 
the United States (Holick, 2006; Looker et al., 2002; Rovner & O’Brien, 2008). However, the 
findings published by Looker and colleagues in 2002, confirmed significant vitamin D 
deficiencies among noninstitutionalized adolescents and adults (Looker et al., 2002).  
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Looker and colleagues analyzed the data collected as part of the Third National Health 
and Nutrition Examination Survey (NHANES III 1988-1994), conducted by the U.S. National 
Center for Health Statistics with the purpose of focusing on the status of 25OHD3 levels in the 
population. The analysis accounted for differences in assessment methods by setting separate 
cutoffs for radioimmunoassay (RAI) and competitive protein binding (CPB) test, since CBP 
results tend to be 30% higher than RAI (Looker et al., 2002). 
The cut-off point for vitamin D deficiency was set as a 25OHD3 blood level of <17.5 
nmol/L (7 ng/mL) for the RAI, equating to <25 nmol/L (10ng/mL) when using the CPB, which 
followed the IOM guidelines from 1997. Based on the cutoff used, less than 1% of the 
participants tested were considered vitamin D deficient. Since there was no agreement for 
insufficiency cutoff at the time of their analysis, the authors used four different ranges for the 
calculations. The RAI values for insufficiency were set at (1) <25 nmol/L, (2) <37.5 nmol/L, (3) 
<50 nmol/L, and (4) 62.5 nmol/L with corresponding CPB values between <37.5 nmol/L and 
87.5 nmol/L (Looker et al., 2002).  
The NHANES III sample included 18,875 participants, 12-years or older, that were 
classified under three different ethnic/racial groups. Seasonal and latitudinal innate variances of 
vitamin D synthesis were identified as confounding factors and corrected early on in the analysis. 
In their analysis, the researchers concluded that regardless of seasonal and latitudinal differences, 
insufficient levels of 25OHD3, defined as <37.5-62.5 nmol/L, were prevalent across all ages, 
gender, race and ethnicity. The calculations found that for all surveyed participants of both 
genders the percentage of occurrence for 25OHD3 of <37.5nmol/L (15ng/mL) was 2-19%; for 
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the same sample the results showed 8-40% when using <50nmol/L (20ng/mL); and, when using 
<62.5nmol/L (25ng/mL), the prevalence was 21-58%.  
The results from the NHANES III led the Center for Disease Control and Prevention to 
recognize that regardless of the food fortification efforts, varied degrees of subclinical 
deficiencies are prevalent among all ages, genders, and latitudes of the country (Looker et al., 
2002). When using the 2011 recommendations for deficiency and insufficiency, up to 40% of the 
population sampled would fall below <50nmol/L or <20ng/mL to be considered deficient (IOM, 
2011b), and up to 58% would meet insufficiency criteria (Holick et al., 2011). 
 
Physiology of Vitamin D  
Once the epidemic of rickets was under control, the interest surrounding vitamin D died 
down. Eventually it was discovered that biological interactions of vitamin D with body systems 
extend far beyond musculoskeletal functions. In the 1970s and 1980s, new discoveries prompted 
the reclassification of calcitriol (1,25OH2D3) as a hormone, launching a new area for scientific 
research (Eyles, Burne & McGrath, 2013; Harms et al., 2011; Holick, 2006; Kesby, Eyles, 
Burne, & McGrath, 2011; Rovner & O’Brien, 2008).  
The abundance of the enzymes that activate and deactivate vitamin D and its receptors in 
the brain suggest that vitamin D is a neurosteroid that regulates brain bioprocesses. The 
expression of vitamin D receptors (VDRs) in the brain is capable of bioactivating 25OHD3 to 
1,25OH2D3 (Groves, McGrath & Burne, 2014; Harms et al., 2011). Expression and activation of 
the vitamin D receptors (VDR) during physiological activities can either exert genetic 
transcriptional modifications or simply act as a membrane-associated rapid response steroid by 
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influencing signaling mechanisms (MARRS) (Eyles, Burne & McGrath, 2013; Gezen-Ak, 
Dursun & Yilmazer, 2013; Kajta et al., 2009; Ridder et al., 2009). The ability to follow genomic 
or non-genomic paths is a commonality shared by other hormones categorized under the same 
family (Eyles, Burne & McGrath, 2013). Post-mortem brain examinations of stroke patients 
showed increased concentration of VDR in the region with infarction when compared to other 
unaffected areas or subjects without a stroke (Ridder et al., 2009). 
The actions of vitamin D on the biological processes related to bone health have been 
studied extensively (Holick et al., 2011). When discussing dynamic biological processes, as with 
bone turnover, it is important to note that multiple body systems, organs, cells types and 
hormones collaborate simultaneously from different locations towards the completion of a 
common biological objective. A concise version of just the demineralization portion follows as a 
way to illustrate the parallel intricacies of biological processes. 
The renal hydroxylation of 25OHD3 to produce 1,25OH2D3 or calcitriol, is tightly 
controlled by the dynamics between serum concentrations of parathyroid hormone (PTH), 
calcium and phosphorous. Generally, when the hypothalamic feedback mechanism signals low 
calcium levels in the blood, it activates compensatory mechanisms which increase PTH secretion 
from the parathyroid glands. PTH works by translocating calcium ions from storage by 
dissolving bone tissue. In addition, when abnormal levels of serum calcium and phosphorous 
concentrations are detected, 1,25OH2D3 interaction with VDRs in bone cells aid increase bone 
dissolution and promote calcium reabsorption in the kidneys (Holick, 2006; Holick, 2007; Holick 
et al., 2011).  
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Meanwhile, expression of VDR in the small intestines improves dietary calcium 
absorption from roughly 10-15% without 1,25OH2D3, to about 30-40% and dietary phosphorous 
improves from 60% to 80%, in an attempt to balance their concentrations. Consequently, as 
phosphorous concentrations rise in the bloodstream, bone tissue secretes molecules to signal the 
kidneys to stop reabsorbing and start excreting excess phosphorous from the blood, and to reduce 
absorption of phosphorous from dietary sources by decreasing renal activation of 25OHD3 to 
1,25OH2D3. Thus, low vitamin D levels dampen the body’s ability to absorb dietary calcium and 
phosphorous negatively impacting bone health and decreasing availability of these minerals 
(Holick, 2006; Holick, 2007; Holick et al., 2011).  
In children, prolonged renal excretion of phosphorus due to secondary 
hyperparathyroidism causes bone deformities and it is known as rickets. Adults have fully 
developed bones, thus the mineralization defects from the inadequate ratio of calcium and 
phosphorus present as softening of the bones, a condition known as osteomalacia. Both 
conditions share symptomatic similarities such as widespread bone and muscle pain, fatigue and 
muscle weakness. Weakened muscles may contribute to difficulty standing, problems with gait, 
recurrent falls and increase of stress fractures. In adults, the direct, long term consequence of the 
bone demineralization is lower bone density, causing osteopenia and osteoporosis. Correction of 
serum vitamin D levels, improve calcium balance and can prevent or correct secondary 
hyperparathyroidism (Holick, 2006; Holick, 2007; Holick et al., 2011; Looker et al., 2002).  
Since the recognition of vitamin D’s hormonal properties, converging evidence from 
epidemiological, experimental and clinical studies has connected low vitamin D to negative 
health outcomes distinct from skeletal outcomes (Braun et al., 2011; Cui et al., 2015; Daubail et 
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al., 2013; McKinney et al., 2011; Moromizato et al., 2013; Turetsky et al., 2015; Wang et al., 
2014) and opened the possibility of supplementation as preventive intervention or treatment 
(Amrein et al., 2014; Gominak & Stumpf, 2012). Retrospective and prospective observations 
support that low levels of vitamin D yielded worse outcomes on cerebrovascular attacks (Daubail 
et al., 2013; Turetsky et al., 2015; Wang et al., 2014), critically ill patients (Braun et al., 2011; 
McKinney et al., 2011; Moromizato et al., 2013), lower cognitive scores, higher score for 
depression inventory (Jamall et al., 2016), chronic fatigue in post-TBI (Schnieders, Willemsen, 
& de Boer, 2012), and increased risk for many neuropsychiatric or neurodegenerative conditions 
(Eyles, Burne & McGrath, 2013; Groves, McGrath & Burne, 2014; Harms et al., 2011; Holick, 
2007; Kesby et al., 2011; Stein, 2015).  
In a systematic review and meta-analysis concerning the association of vitamin D 
deficiency and brain volumetric variations, Annweiler and colleagues (2014), concluded that 
subjects with low vitamin D had lesser brain volume and larger ventricles when compared to 
control subjects. Taking into account that vitamin D is a relatively new research interest, only a 
few studies met inclusion criteria for the review, thus the connection of vitamin D to brain 
atrophy remains to be confirmed (Annweiler et al., 2014). Similar volumetric findings from 
animal studies have also been reported (Eyles, Burne & McGrath, 2013; Groves, McGrath & 
Burne, 2014; Kesby et al., 2011). 
 Scientists from the University of Queensland, Australia, have done extensive work 
exploring the neuronal implications of vitamin D in the brain, including distribution mapping of 
VDR and the enzymes for activation/deactivation (1,25-hydroxylase and 24- hydroxylase) in the 
human brain and the extraordinary similarities in the rat brains. Their collaborative work has 
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created a large databank supporting the neuroprotective qualities of vitamin D (Eyles, Burne & 
McGrath, 2013; Groves, McGrath & Burne, 2014; Harms et al., 2011; Kesby et al., 2011). Their 
experiments in rats has provided compelling evidence implicating low vitamin D level during 
gestational and early developmental age to structural alterations of the brain, genetic 
modifications linked to neuronal potentiation, increased cell proliferation, decreased apoptosis 
and cell differentiation, and deviations of dopamine (DA) signaling and breakdown (Eyles, 
Burne & McGrath, 2013; Groves, McGrath & Burne, 2014; Kesby et al., 2011). Epidemiological 
studies by the same group, demonstrated a significant risk for schizophrenia was inversely 
related to 25OHD3 levels, with levels <16ng/mL displaying a twofold increased (Eyles, Burne & 
McGrath, 2013).  
Studies suggest an association between vitamin D and the incidence of neuropsychiatric 
conditions including depressive disorders, schizophrenia, Alzheimer disease, Parkinson’s 
disease, cognitive decline, dementia and autism, among others. For some of these findings 
reverse-causation has not yet been discarded (Cui et al., 2015; Groves, McGrath & Burne, 2014; 
Kesby et al., 2011). Groves, McGrath and Burne (2014) organized this information (see figure 10 
below) to illustrate the type of studies and the findings categorized by disease (Groves, McGrath 
& Burne, 2014).  
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Figure 10: Strength of evidence based on animal studies, clinical trials, and epidemiological studies  
that show evidence of an association between vitamin D and various disorders.  
Numbers in boxes correspond to reference numbers (Groves, McGrath & Burne, 2014, p. 128).  
Based on the evidence from prospective cohort studies, there is reason to believe that 
vitamin D deficiency and insufficiency may contribute to cognitive decline in adults. Other 
prospective studies have found similar evidence, in addition to linking marked vitamin D 
deficiency to a significantly increase of the risk for Alzheimer disease and vascular dementia in 
the 30 year follow up. However, failure to collect baseline cognitive data or to use objective tools 
to test cognitive abilities limits the significance the findings (Toffanello et al., 2014).  
Recent retrospective and observational studies found that prehospitalization low vitamin 
D level is a solid predictor of mortality for ICU patients during hospitalization (Braun et al., 
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2011; McKinney et al., 2011; Moromizato et al., 2013), and at 30, 90 and 365 days from 
admission mortality remained high for 25OHD3 levels <29ng/mL prior to hospitalization (Braun 
et al., 2011). Another study revealed a strong connection between low 25OHD3 among critically 
ill and an elevated likelihood of developing acute kidney injury (Moromizato et al., 2013).  
A randomized double-blind trial of 492 ICU patients with 25OHD3 < 20ng/mL were 
given either high doses of vitamin D or placebo for a period of five months. No statistical 
significance was found in the length of hospitalization or time in the ICU. However, the 
comparison of the fatality rates during hospital stay and at six months were lower for the group 
receiving high-dose calcitriol supplementation (28.6% and 34.7% respectively) versus the 
placebo group (46.1% and 50% respectively). After adjusting for covariate only the mortality 
rate during hospital stay remained significant (Amrein et al., 2014). The results from this clinical 
trial did not observe significant effect on the outcomes for patients with deficiency or 
insufficiency prior to admission in the ICU, or even after levels were improved by aggressive 
supplementation (Amrein et al., 2014). However, this peculiarity may be explained by results 
from laboratory experiments and clinical trials that suggested levels prior to cell trauma or stress 
offer the best neuroprotection, also the duration/timing of 25OHD3 exposure may have big 
implications in responses (Kajta et al., 2009; Obradovic et al., 2009), and lastly, the effectiveness 
of vitamin D may by directly related to a specific range of concentration (Atif et al., 2013; 
Gominak & Stumpf, 2012; Hur et al., 2014; Kajta et al., 2009). 
Low levels of 25OHD3 in patients suffering from headaches who were also diagnosed 
with a sleep disorder and the discovery of high presence of VDR in regions of the hypothalamus 
and brainstem known to regulate sleep, led researchers to hypothesize that vitamin D could 
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possibly influence sleep patterns. A two year long, uncontrolled clinical trial of 1,500 patients 
with complaints of headache, poor sleep and fatigue found a marked sleep quality improvement 
following vitamin D supplementation regardless to the sleep disorder diagnosis. However, 
decreased fatigue and sleep improvements were best achieved when 25OHD3 concentration 
fluctuated between 60-80 ng/L (Gominak & Stumpf, 2012).  
Studies have found that fatigue and sleep disorders are prevalent following a TBI 
(Chauhan, 2014; Jamall et al., 2016; VA/DoD, 2016). A recent cohort study of TBI patients with 
complaints of chronic fatigue, found that vitamin D levels <20ng/mL was the number one factor 
shared by 65% of the cohort, when compared to poor sleep (54%), anxiety (36%), inadequate 
levels of growth hormone (16%) and gonads hormonal deficiencies (9%). It is worth noting that 
26.6% of the remaining was considered to have insufficiency with 25OHD3 levels <30ng/mL, 
thus nearly 92% was bellow 30ng/mL. The incidence and severity of chronic fatigue, sleep 
problems, attention and cognitive deficits after TBI are strongly and intricately related 
(Schnieders, Willemsen, & de Boer, 2012) and improvements in post-TBI sleep disturbances 
showed significant decrease of other neuropsychological impairments related to TBI (Chauhan, 
2014).  
It is worth noticing the work of researchers from Emory University, in Atlanta, Georgia, 
since they have made crucial contributions to the areas of stroke and TBI research over the last 
two decades. They focused on targeting multiple processes of acute head trauma by combining 
two neuroprotective agents with the idea that the combination would exert synergistic benefits. 
This concept was accepted by a panel of the National Health Institute with the idea of boosting 
favorable outcomes and functionality following brain injury. The preclinical results with 
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1,25OH2D3 administrated concomitantly with progesterone yielded significant improvements in 
TBI and stroke models (Atif et al., 2013). Unfortunately, this hormonal combination failed to 
translate with the same success as the clinical trials advanced (Stein, 2015). The Emory 
University laboratories have demonstrated that vitamin D attenuates the inflammatory response, 
protects neuronal and glia cells against apoptosis, exerts antioxidant protection, protects against 
excitotoxicity from glutamate, may impart a positive impact in certain functionality outcomes 
after ischemic damage (Atif et al., 2013), strengthen the integrity of the BBB and reduces 
damage by oxidative stress (Won et al., 2015). 
Vitamin D neuroprotection. 
Vitamin D deficiency has been implicated in defective actions of macrophages involving 
the secretion of pro-inflammatory cytokines and phagocytic performance. The connecting 
element between the innate immunity and stimulation of toll-like receptors is vitamin D. 
Moromizato and colleagues (2013), hypothesized that the elevated likelihood for sepsis or septic 
shock among critically ill patients is due to these the toll-like pathways interacting with vitamin 
D. VDR expression is induced by peripheral and neuronal immune cells activation. After 
multivariable adjustment and random selection validation sub-analysis, vitamin D levels 
<15ng/mL prior to admission were associated to a 2.5-fold increment on the risk for sepsis or 
septic shock (Moromizato et al., 2013). 
Stressed brain cells increase VDR expression and 1,25OH2D3 activation in cultured 
animal cells (Fu et al., 2013; Obradovic et al., 2009) and in the brain of deceased patients with a 
stroke. Similar findings concerning brain cells under ischemic stress were described by Ridder 
and colleagues (2009), showing VDRs translocation into the nucleus from vitamin D hormone 
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stimulation followed the ischemic event (Ridder et al., 2009). Vitamin D significantly decreased 
cell death from glutamate excitotoxicity (Kajta et al., 2009), from absence of oxygen-glucose 
(ischemia/reperfusion model) (Atif et al., 2013), from oxidative stress (Hur et al., 2014) and due 
to tumor necrosis factor apoptosis-inducing ligand (TRAIL) (Obradovic et al., 2009). 
Preclinical experiments have shown that vitamin D neuroprotective gains may require 
preloading or pretreatment preceding exposure to harmful incident (Kajta et al., 2009; Obradovic 
et al., 2009), and may be dose- and time-dependent. For example neurons from different regions 
of the brain require higher or lower doses than others for the same benefit or in cases of delayed 
treatment, higher concentrations may be required to reach therapeutic benefits (Kajta et al., 
2009).  
Recent experiments confirm that activated microglia intensified the expression of 1,25-
hydraxolase and VDR preceding depression of nitric oxide (NO) synthesis and a 90% 
improvement on cell viability, implying suppression of activated microglia by the active form of 
vitamin D (Hur et al., 2014). Activated microglia promotes neuroinflammation by stimulating 
mitogen-activated protein kinase (MAPK) pathways. However, vitamin D is capable of negative 
regulating the phosphorylation of p38 (Huang et al., 2015; Hur et al., 2014; Obradovic et al., 
2009), extracellular signal-regulated kinase (ERK) (Fu et al., 2013; Huang et al., 2015) and Jun-
N-terminal (JNK) (Huang et al., 2015) MAPK pathways. Increase in NR3 subunit by vitamin D, 
dampens phosphorylation of ERK pathway by mediation of a nuclear binding transcription factor 
(cAMP/Ca2+ response element binding protein or CREB) (Fu et al., 2013). Vitamin D’s 
obstruction of p38 and ERK expression significantly hinders inducible nitric oxide synthase 
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(iNOS), reduces intracellular production of ROS (Huang et al., 2015) and buildup of NO (Huang 
et al., 2015; Hur et al., 2014).  
1,25OH2D3 also prompt a marked decline in synthesis and signaling involving pro-
inflammatory mediators such as interleukin-6 (IL-6) (Atif et al., 2013; Huang et al., 2015), 
macrophage-inflammatory protein-2 (MIP-2) (Huang et al., 2015), and nuclear factor kappa-B 
(NFκB) concentrations (Atif et al., 2013; Won et al., 2015). The significant declines of IL-6 and 
MIP-2 at protein and mRNA sites were largely mediated by the inhibitory effects on p38, ERK 
and JNK (Huang et al., 2015).  
Hypoxic and mitochondrial injury stimulates activation of NFκB pathway. The activated 
NFκB translocates into the nucleus, where p65 subunits acts as a transcription factors by binding 
to a gene that upregulates MMP-9 expression (Won et al., 2015) and IL-6 (Fernández-Gajardo et 
al., 2014) promoting neuronal inflammation (Atif et al., 2013). In vitro experiments showed a 
marked decline in concentrations and expression of NFκB after vitamin D was added to brain 
cultured cells. Thus blocking phosphorylation of NFκB reduces inflammation and disruption of 
the BBB (Atif et al., 2013; Won et al., 2015). 
Atif and colleagues (2013) from Emory University, found outstanding efficacy of vitamin 
D in elevating heme oxygenase-1 expression to attenuate oxidative damage after ischemia, as 
demonstrated by a twofold increment (Atif et al., 2013). Mitigation of free radical damage 
increasingly causing lipid peroxidation and degradation of DNA is ameliorated by vitamin D 
(Charier et al., 2015; Won et al., 2015). Vitamin D cause only a minor reduction of 
malondialdehyde (a biomarker present following membrane oxidative degradation) 
concentrations, however it produced a substantial boost in superoxide dismutase. Superoxide 
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dismutase is the potent antioxidant enzyme behind the protective catalysis of superoxide (Ekici, 
Ozyurt & Erdogan, 2009).  
A combined in vitro/in vivo study showed that calcitriol, when administered within 30 
minutes following a hypoxic-ischemic event, offered significant reduction of brain injury. The in 
vitro portion of the study showed that glutamate excitotoxicity damage is significantly weakened 
by administration of calcitriol to cultured cortical neuron and glia cells. Pretreatment and higher 
doses of calcitriol yielded superior protection. Interestingly, these positive benefits were not 
observed in cerebellar cells (Kajta et al., 2009). Vitamin D can ameliorate cell damage from 
glutamate toxicity by increasing NR3 expression, subsequently antagonizing proinflammatory 
extracellular signal-regulated kinase (ERK) MAPK pathway thought the activation of a nuclear 
transcription factor CREB. CREB expression has an anti-apoptotic effect, stimulates 
neurogenesis and may be helpful in protecting against glutamate excitotoxicity (Fu et al., 2013).  
Extracellular glutamate in excess results in hyper-stimulation of low voltage calcium 
channel and generates calcium influx rising to toxic levels (Fu et al., 2013). Positive modulation 
of low voltage calcium channel subunit A1C (LVCC-A1C) has been observed in cultured 
neurons after suppression of VDR (Gezen-Ak, Dursun & Yilmazer, 2013). Downwards 
regulation of the LVCC-subunits is unleashed by vitamin D or VDR and thought to block 
calcium influx. Additionally, vitamin D enhanced expression of calcium binding proteins thus 
limiting free ions inside the cell (Groves, McGrath & Burne, 2014).  
After exposure of cortical neurons to amyloid β, VDR expression was totally invalidated. 
Meanwhile, treatment with vitamin D protected cortical neurons against toxicity from amyloid β 
proteins through suppression of LVCC-A1C while stimulating the expression of VDR. Amyloid 
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β accumulation had an opposite effect by enhancing LVCC-A1C and suppressing VDR 
expression. This is interesting, since amyloid β accumulation has been proposed as a potential 
etiology for Alzheimer disease and other dementias (Gezen-Ak, Dursun & Yilmazer, 2013). 
Knowing that there is an upsurge of both amyloid β and its precursor protein after head trauma 
(Fernández-Gajardo et al., 2014), and that it can suppressed vitamin D activities during the 
secondary injury phase opens the possibility for therapeutic interventions. Studies on Alzheimer 
patients showed that vitamin D improves amyloid β elimination and phagocyte engulfment in the 
brain (Gezen-Ak, Dursun & Yilmazer, 2013).  
Vitamin D considerably reduced permeability of viable brain endothelial cells under low 
oxygen conditions though dose-mediated protection on the integrity of proteins along the tight 
junctions, the space between endothelial cells that supports BBB integrity. Interruption of the 
BBB during hypoxia or ischemia is mostly driven by excessive generation of ROS and NO 
damaging cellular structures. VDR expression directed the antioxidant effects of vitamin D in the 
protection of the BBB permeability by hindering oxidative stress.  
Thus 1,25OH2D3 and VDR mediate the protection of tight junctions of endothelial cells 
in the BBB in several ways (Won et al., 2015) by negatively impacting the activity of matrix 
metalloproteinases (MMP), a group of enzymes that together with nuclear factor kappa-B (NF-
κB), are known to disrupt cellular membrane permeability subsequential to ROS stimulation. 
Matrix metalloproteinase-9 (MMP-9) is an enzyme that sponsors mending of cell membranes. To 
achieve restoration the MMP-9 simultaneously disintegrates tight junction proteins to repair the 
membranes, thus worsening dysfunction of the BBB (Mayer et al., 2013; Won et al., 2015). As 
MMP-9 concentrations grow following brain injury, it paves the way for BBB disruption through 
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protein degradation (Won et al., 2015). MMP-9 is a proinflammatory mediator capable of 
activating neuroglia cells (Mayer et al., 2013). After a hypoxic event, vitamin D is able to 
promote the BBB impermeability by reducing MMP-9 expression (Won et al., 2015). 
The abovementioned, are extremely important for brain cell protection after acute trauma, 
since disruption of the BBB precedes infiltration of peripheral and blood cells into the brain 
compartment that can result in neuronal and glia apoptosis (Fernández-Gajardo et al., 2014). 
Blood is so detrimental to the brain that hemorrhages are indicators for more advanced 
neurological impairment and higher mortality risk. When lysed blood comes into contact with 
neuronal cells it exacerbates the cellular stress from excess calcium. Recent laboratory data 
showed that axonal fragmentation began 12 hours after exposure of neuronal cultures to lysed 
blood and progressed until the entire axon was destroyed. Vitamin D application showed 
significant protection against blood-induced axonal fragmentation, but it did not offer a 
significant protection against substances emitted from blood clotting (Charier et al., 2015).  
In vivo experiments indicated that 1,25OH2D3 administration after an ischemic incident 
induces smaller infarction volume (Fu et al., 2013; Kajta et al., 2009) and increased cell survival 
(Atif et al., 2013), however, pretreatment exerted better results (Kajta et al., 2009). Data from 
studies on ischemic strokes are provided, since clinical data of TBI, vitamin D, and ischemic 
injury was not available at the time of this review. These findings may explain the observations 
from retrospective and prospective studies from China, France and the USA, in which an inverse 
association between vitamin D and infarction size was reported. Low vitamin D prior to 
admission showed larger infarct volume (Turetsky et al., 2015; Wang et al., 2014), increase 
severity on admission (assessed with the National Institutes of Health Stroke Scale) (Daubail et 
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al., 2013; Wang et al., 2014) and longer hospitalization length after an ischemic stroke (Wang et 
al., 2014), also served as an independent predictor for the magnitude of the outcomes. Two of the 
studies found that low 25OHD3 predicted worse functionality outcomes at hospital discharged 
(Wang et al., 2014) and at 90-days (Turetsky et al., 2015) and survivors were correlated with 
higher serum 25OHD3 (Wang et al., 2014). Turetsky and colleagues (2015) stated that for every 
10ng/mL reduction in 25OHD3 levels, there was a twofold increase for inferior outcomes at 90 
days post-ischemic brain attack, and proposed exploration of 25OHD3 as a biomarker to identify 
patients with heighten vulnerability for worse prognosis (Turetsky et al., 2015). All of the 
observational studies used difference vitamin D references for their analysis, as seen on table 3. 
Table 3: Incidence of vitamin D deficiency as defined by the above referenced studies. 
Stroke patients Daubail et al., 2013 Turetsky et al., 2015 Wang et al., 2014 
Country of origin France China USA 
Serum 25OHD3  <10ng/mL <29.9ng/mL <20ng/mL 25OHD3 
Percentage of 
participants 
33% 64% 68% 
 
Significance of Vitamin D on Brain Health  
The neurological implications of vitamin D levels and the mechanisms involved with 
brain functions are still being assessed. Compelling evidence indicates that 1,25OH2D3 may 
prevent brain cell damage by interacting with about 170 genes following ischemic injury and 32 
transcription factors with gene upregulation potential (Ridder et al., 2009). An in vitro study 
using cultured neuronal stem cells from human origin, found more than 180 proteins involved in 
neurological processes and neurogenesis were expressed after the cells came into contact with 
1,25OH2D3 (Obradovic et al., 2009).  
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Noteworthy attenuation of the expression of iNOS, IL-6 and MIP-2 has been observed 
with calcitriol (Huang et al., 2015). Genomic regulations of ion voltage channels on cell 
membranes have been reported to aid in maintain ionic balance (Gezen-Ak, Dursun & Yilmazer, 
2013; Groves et al., 2014). Thus, deficiency or insufficiency of vitamin D may enhance 
vulnerability when facing the pathological alterations of TBI. 
In summary, available biological data supports that 1,25OH2D3 and VDR expression 
have regulatory influences in known secondary responses that follow a TBI. Given the results, 
vitamin D promises to be a therapeutic agent to prevent the activation or slow down the 
progression of the TBI-related inflammatory responses and BBB disruption. The emerging 
literature associating vitamin D status with the prevention, prognosis, and progression of a large 
number of neurological deficits and long-term neurodegeneration supports the need to expand 
research. 
 
Vitamin D Status Among the Military Population 
New discoveries concerning vitamin D actions in multiple biological processes, as well 
as neuroprotective features, could be relevant to military personnel recovering from TBI (Cui et 
al., 2015; Wentz, Eldred, Henry, & Berry-Caban, 2014). Although only a few studies have 
evaluated vitamin D levels among active military and veterans, the available evidence suggests a 
high prevalence of deficiency and insufficiency (Alazzeh et al., 2015; Andersen et al., 2010; 
Bailey, Manning & Peiris, 2012; Hiserote et al., 2016; Wentz et al., 2014).  
A retrospective study of active duty (1,928) and veteran (1,125) military personnel, 
examining medical records for 3,053 samples at the Womack Army Medical Center, Fort Bragg, 
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North Carolina, showed that 57.3% of participants had either vitamin D deficiency or 
insufficiency, regardless of the 35.1°N latitude of the sample. The findings (reference table 4 and 
5 below) showed that 20.4% of the participants were deficient, 36.9% tested at insufficient levels 
and 42.7% were between 30-100ng/mL (Hiserote et al., 2016).  
Table 4: Service members by 25OHD3 level (Hiserote et al., 2016). 
 Deficiency 
<20ng/mL 
Insufficiency 
21-29ng/mL 
Sufficiency 
30-100ng/mL 
All service members n= 623 n= 1,127 n= 1,302 
Mean 25OHD3 14.65 + 3.44 24.77 + 2.82 38.94 + 9.83 
 
Table 5: Vitamin D levels according to military status (Hiserote et al., 2016). 
 Active duty (n= 1,350) Veterans (n= 1703) 
Mean 25OHD3 27.79 + 11.28 30.47 + 12.55 
 
To this date, perhaps the most significant study evaluating vitamin D levels among 
military patients is the retrospective analysis of 15,340 individuals from six different facilities in 
the southeastern United States. Although the sample was primarily comprised of white males 
with an average age of 66.5 years, vitamin D deficiency (<20 ng/mL) was significant in all six 
sites, even after correcting for seasonal and latitudinal variances. In fact, the highest vitamin D 
levels were below 35 ng/mL at all locations, except for one site (Huntington) where it was 
between 38-39 ng/mL. Moreover, deficiency was independently related to higher cost of health 
care across the entire sample (as seen on figure 11). Health care cost was at least 70% higher for 
patients who were deficient and did not receive a vitamin D follow up test in comparison to who 
were either deficient or received a vitamin D follow up test. The deficient patients without a 
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follow up test had nearly 300% higher health care cost than the non-deficient who received 
follow up testing (Bailey, Manning & Peiris, 2012). 
 
Figure 11: Total inpatient costs by VA site and vitamin D deficiency status  
(Bailey, Manning & Peiris, 2012, p. 74). 
A retrospective study analyzed of 3,608 American female veterans tested during a period 
of ten years (2001-2010), found a 44% deficiency of 25OHD3 (<20 ng/mL) with a higher 
incidence among minority veterans (Alazzeh et al., 2014). Another retrospective analysis of 
vitamin D status among critically ill veterans between 1999 and 2009, found that 38% tested 
deficient at <20ng/mL and 60% tested within the range for insufficiency (<30ng/mL) (McKinney 
et al., 2011).  
A pilot study examined the impact of 8 weeks of basic combat training (BCT) on the 
vitamin D levels on new female recruits at the US Army BCT at For Jackson, South Carolina. 
The data from the randomized control trial was collected during summer/fall training and used to 
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evaluate vitamin D serum concentrations of the 74 trainees. The comparison of 25OHD3 levels 
from baseline and the end of the 8 weeks of basic combat training showed the mean levels 
declined from 72.9 +30.0nmol/L to 63.3 +19.8nmol/L, with lowest levels among non-Hispanic 
black. This study documented a decline in 25OHD3 levels among young female recruits during 
the summer-fall training, regardless of the time spent outdoors (Andersen et al., 2010).  
The IOM and TES concluded that screening of vitamin D status for healthy, 
asymptomatic individuals is not necessary, unless there are identifiable risks suggesting 
otherwise (Holick et al., 2011; IOM, 2011b). Giving the significance of the evidence showing 
high health care cost with low vitamin D levels and progressive decreased during outdoor 
military training, it is appropriate to recommend evaluation of vitamin D optimization for active 
duty members and veterans.  
Vitamin D: Advancing Future Research.  
In their review of literature, Wentz and associates (2014) suggest that achieving optimal 
levels of vitamin D prior to injury may protect and improve rehabilitation efforts of wounded 
soldiers, while improving their outcomes (Wentz et al., 2014). There may also be the potential 
added benefits of improving survival rates for soldiers in critical condition, reducing disease 
progression and decreasing clinical symptoms (Alazzeh et al., 2015; Cui et al., 2014; Eyles, 
Burne & McGrath, 2013; McKinney et al., 2011; Moromizato et al., 2013; Toffanello et al., 
2014; Wentz et al., 2014).  
Advantages of working with military subjects include easy access to conduct health 
exams and laboratories prior to head trauma exposure. Monitoring and supplementation 
interventions can be performed within cohorts with shared characteristics. Additionally, 
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designing studies with subjects under a two or three year contract or with lifelong military 
careers may improve attrition rates.  
In order to advance vitamin D research and practices it is necessary to address the lack of 
international reference values for screening, the need to standardize the assay methods, and 
reanalyzed the epidemiological and clinical findings. 
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CHAPTER 5: DISCUSSION 
Active duty military and veterans share a history of exposure to TBI. TBI is responsible 
for inflammatory and metabolic processes with long-term progression. Screening of vitamin D 
status is a reasonable first step, given that adequate vitamin D levels prior to brain injury have 
been shown to exert neuroprotective actions and slow the pathological changes after head 
trauma.  
The complexity of TBI management comes with acute and chronic pathologies. Clinical 
presentation is as individualized and unique as the injury itself. The progression, outcomes and 
response to current intervention protocols have made TBI a difficult disorder to treat.  
 To date, most research of TBI and vitamin D has been done in animal models. Thus far, 
translating these models into clinical trials has proven to be challenging. However, in order to 
improve knowledge, successes and failures are inherent, and arguably necessary in research.  
The idea of having standard, acceptable measures to better guide future study of TBI has 
been a long standing goal of the scientific and clinical communities. The shortcomings of the 
methods used to measure outcomes contribute to the large number of clinical trial failures and 
continue to hold back prospects of fulfilling this goal. 
Neuroinflammatory pathophysiological alterations of ischemic stroke parallel those of 
TBI. In reviewing human trials and observational studies of patients with hypoxic/reperfusion 
injuries, it was evident that vitamin D exerts a neuroprotective action. It reduces the volume of 
the injury, improves symptoms and prognosis, decreases mortality, lowers disability and is 
associated with better functionality. There is still much to answer about possible physiological 
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impact of low and insufficient vitamin D concentrations on health and thus far, causality is not 
even part of the conversation. 
However, it is hard to ignore the inconsistencies in vitamin D classification and reference 
range used by many of the studies. Variations in optimization practice guidelines add to the 
challenges surrounding a complex field and compound to the difficulties of designing 
interventional trials. Consistency and validity of measuring methods are at the foundation of high 
quality research and should be prioritized. Only time will tell if the scientific and medical 
communities can indeed achieve consensus and provide the prevention and interventions of 
vitamin D. Collaboration to develop a common set of guidelines will be needed, if health care 
providers are to address clinical and subclinical deficiencies among military service personnel 
utilizing evidence-based practices.  
The number of combat injured service personnel surviving serious injuries will continue 
to rise. Better, consistent diagnostics and treatments should be a priority for the nation. Accurate 
diagnosis and high quality TBI clinical management have the potential to improve the lives of 
veterans and improve their reintegration as civilians.  
The scarcity of human studies on the neuroprotective effects of vitamin D on TBI-related 
outcomes, confirms that there is a need in this area. Future research of TBI management could 
include exploring the relationship of vitamin D screenings before combat exposure and post-TBI 
outcomes. It could also incorporate prognosis predictions based on 25OHD3 levels and 
investigating the possibility of long-term supplementation for the prevention and treatment of 
chronic neurodegeneration after combat-related head trauma.  
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CHAPTER 6:  CONCLUSION 
This review found compelling evidence supporting that the acute and chronic 
pathological changes following TBI are closely associated with the neuroprotective mechanisms 
of vitamin D. Calcitriol administration is considered safe, relatively low cost and screening risks 
are fairly low. The question of the potential benefit of a supplementation program for military 
personnel merits further inquiry. Furthermore, the evidence supports that an optimization 
program for active duty and veterans promises to lower cost of health care. Thus, the potential 
argument concerning the cost of vitamin D screening pales against the return on investment and 
the human capital gains.  
Studies evaluating vitamin D status among military personnel shows that deficiency and 
insufficiency are prevalent, regardless of age, gender, ethnic background, or military status. 
Ongoing warfare will continue to expose military service personnel to the risk of TBI. Sufficient 
preclinical studies have shown that vitamin D neuroprotection is enhanced by preloading the 
cells before exposure to trauma and in some instances neuroprotection can only be achieved by 
meeting a specific range. Mounting evidence from clinical and epidemiological studies confirm 
that low vitamin D levels predispose patients to poorer health consequences.  
Soldiers, veterans and their families eagerly await evidence-based clinical practices that 
can reduce disease burden by improving outcomes, recovery and minimizing long-term sequelae. 
Based on the evidence reviewed, the medical community can no longer afford to ignore vitamin 
D.  
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Appendix A: Methodology 
Searched subject headings, subjects and abstracts for:   
  
(("sclerosis" OR "sclerotic" OR "autoimmune*" OR "Hyperammonemia" OR "spinal cord" OR "spine" OR 
"tumor" OR "cancer" OR "carcinoma" OR "ethanol" OR "cardio*" OR "coronary" OR "renin-angiotensin" OR 
"osteoporosis" OR "bone loss" OR "bone resorption" OR "respirat*" OR "lung" OR "muscle" OR "skin" OR 
"liver" OR "kidney" OR "renal" OR "bowel diseases" OR "malabsorption syndrome" OR “digestive” OR 
"thiamine" OR “folate” OR “B12” OR “B6” OR "vitamin A" OR “zinc” OR "diabetic" OR "insulin" OR 
"hemodialysis" OR "parathyroid" OR "thyroid" OR "dehydroepiandrosterone" OR "vestibul*" OR “hearing” OR 
"visual" OR “retina” OR "sepsis" OR "sperm" OR "dopamine" OR "ovarian" OR “pregnancy” OR “aging” OR 
“65 years” OR "neonatal" OR "newborn" OR "infant" OR “children” OR “Cerebral Cavernous” OR “depress*” 
OR “epilepsy” OR “shaken baby” OR “antipsychotic” OR “sleep disorder”) OR ("Parkinson" OR "autism" OR 
“Alzheimer”) 
EXCLUSION CRITERIA TERMS 
 
(“brain” OR “cerebral” OR “axonal” OR "brain injur*" OR 
"brain trauma" OR "brain dysregulate*" OR "brain dysfunct*"  
OR "traumatic brain injury" OR "brain concussion" OR "head 
trauma" OR "concussion" OR "blast-related traumatic brain*" 
OR "post-concussive" OR "post-traumatic brain" OR 
"neuroinflammat*" OR “secondary damage” OR “primary 
damage” OR “secondary injury” OR “primary injury”) 
(“inflammatory cytokines” OR “neuroinflammat*” OR “immune regulat*” OR “inflammatory mediator” OR 
“immune system” OR “MAPK” OR “neuron* disruption” OR “blood-brain barrier” OR “BBB” OR ”BBB 
leakage” OR “brain-blood” OR ”membrane leakage”  OR “L-type calcium channels” OR “calcium channel” OR 
“ca* influx” OR “brain intracellular calcium” OR “reactive oxygen species” OR “ROS” OR “oxidative stress” OR 
“oxidative damage” OR “ion gradients” OR “neurotoxicity” OR “excitotoxic*” OR “excitotoxicity” OR “cerebral 
edema” OR “neuroedema” OR “apoptosis” OR “neurotrophic” OR “neurotrophic factor” OR “nerve growth 
factor” OR “NGF” OR “proliferation,” OR ” lipid peroxidation” OR “hypoxi*” OR “cerebral ischemia” OR 
“VDR*” OR “vitamin d receptor” OR “1α-hydroxylase” OR “VDR binding” OR “antioxidant” OR 
“neuroprotect*” OR “regulat*” OR “modulat*” OR “Neuroprotective Agent” OR “cytotoxic*” OR 
“pathogenesis”) 
n = 53 
AND 
("vitamin D*" OR "vitamin-D*" OR 
"Cholecalciferol" OR "calciferol" OR 
"calcitriol" OR "*dihydroxyvitamin D" 
OR "soltriol" OR "25OHD*" OR 
"25(OH)D*" OR "1,25(OH)2D*") 
n = 773 
n = 14 
Further exclusion parameters: (1) studies related to science or medical specialties other than 
neurology; (2) sample size of 1 patient; (3) age group: neonates, child* or infant or embryonic or 
pediatric or adolesce* or 0-18 years or birth or pregnancy or aged or aging or elderly or over 65; 
(4) did not include at least one of the topics from the inclusion criteria. 
 
Articles were hand reviewed for inclusive criteria:  
1) vitamin D neuroprotection and, 2) physiological alterations related to inflammation, interruption 
of BBB, oxidative stress, and calcium concentration disruption.  
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Appendix B: Inflammatory Mediators  
Pro-inflammatory 
mediators 
Action Vitamin D 
Mitogen-activated 
protein kinase 
(MAPK) are 
initiated via 
expression of the 
NMDA receptor:  
1. p38  
2. extracellular 
signal-regulated 
kinase (ERK) 
3. Jun-N-terminal 
(JNK) 
• Initiate neuroinflammatory 
response by increasing synthesis 
of pro-inflammatory mediators 
(ROS, IL-6 and MIP-2) and NO 
accumulation (Huang et al., 
2015). 
• ERK: signaling cascade to 
initiate apoptosis (Fu et al., 
2013). 
• Suppresses phosphorylation of p38, 
ERK and JNK MAPK pathways, 
reduces NO accumulation and ROS 
production and significantly 
decreases IL-6 and MIP-2 (Huang 
et al., 2015). 
• Restore concentration of the NR3A 
subunit by lessening its 
degradation, consequently 
triggering expression of the 
calcium-response element binding 
protein (p-CREB) (Fu et al., 2013). 
• Hinder the phosphorylation 
sequence of p38 MAPK and 
consequently inhibits expression of 
inducible nitric oxide synthase 
(iNOS), accumulation of nitric 
oxide (NO) and synthesis reactive 
oxygen species (ROS) (Hur et al., 
2014). 
Reactive oxygen 
species (ROS) 
synthesis 
• Lipid peroxidation (Ekici et al., 
2008), degradation of DNA 
(Fernández-Gajardo et al., 2014) 
and initiates endothelial and 
neuronal apoptosis (Won et al., 
2015).  
• Activates NJK MAPK, triggers 
cellular edema, calcium influx 
and metabolic collapse 
(Fernández-Gajardo et al., 2014).  
• Decrease neurotrophic factors, 
worsen cognitive decline and 
neuronal communication, and 
increase BBB permeability 
(Fernández-Gajardo et al., 2014). 
• Promotes expression of NFκB 
and MMP-9 (Won et al., 2015). 
• Reduces intracellular production of 
ROS by obstructing p38 and ERK 
expression in cultured brain cells 
(Huang et al., 2015). 
• Significant improves cell viability 
following exposure to ROS (Won 
et al., 2015). 
• Mitigates free radical damage 
increasingly causing lipid 
peroxidation and ameliorates 
degradation of DNA (Charier et al., 
2015; Won et al., 2015). 
• Vitamin D significantly inhibited 
mitochondrial ROS production 
through VDR expression 
endothelial cells (Won et al., 2015). 
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Pro-inflammatory 
mediators 
Action Vitamin D 
Nitric oxide (NO) 
accumulation 
• Suppresses enzymatic activity in 
the mitochondria thus reducing 
adenosine triphosphate (ATP) 
production (Fernández-Gajardo 
et al., 2014; Huang et al., 2015; 
Hur et al., 2014). 
• Foster ROS synthesis (Huang et 
al., 2015). 
• Obstruction of p38 and ERK 
expression significantly decreases 
buildup of NO (Huang et al., 2015; 
Hur et al., 2014). 
• Expression of 1,25-hydraxolase 
and VDR preceded decline of nitric 
oxide (NO) synthesis and a 90% 
improvement on cell viability (Hur 
et a., 2014). 
Inducible nitric 
oxide synthase 
(iNOS) 
• Linked to cognitive deficits in 
older adults (Huang et al., 2015). 
• Significantly hinders iNOS 
expression by limiting activation of 
p38 and ERK (Huang et al., 2015). 
Matrix 
metalloproteinase-
9 (MMP-9) 
upregulation 
• MMP-9 is capable of activating 
neuroglia cells (Mayer et al., 
2013). 
• Sponsors mending of cell 
membranes, but at the same time 
it disintegrate proteins of the 
BBB tight junctions (Mayer et 
al., 2013; Won et al., 2015). 
• As concentration rises after 
injury, it produces protein 
degradation that leads to 
interruptions of BBB (Won et 
al., 2015). 
• Protects BBB integrity after a 
hypoxic event, by reduced 
expression of transcriptor factor 
that promotes MMP-9 (Won et al., 
2015). 
Nuclear factor 
kappa-B (NFκB) 
• Activation of NFκB pathway 
allows it to translocate into the 
nucleus, where p65 subunit acts 
as a transcription factor by 
binding to a gene that 
upregulates MMP-9 production 
(Won et al., 2015). 
• NFκB binding to genes increases 
IL-6 (Fernández-Gajardo et al., 
2014) promoting neuronal 
inflammation (Atif et al., 2013). 
• Marked decline in concentrations 
of NFκB (Atif et al., 2013), blocks 
phosphorylation and prevents 
translocation and gene expression. 
Thus, protects BBB integrity by 
reduction on MMP-9 
concentrations (Won et al., 2015). 
Toll-like receptors 
(TLR) 
• Proteins capable of recognizing 
indicators of tissue damage and 
aid in communication of 
• Vitamin D is the mediator between 
TLR and activation of innate 
immunity. Low levels had a 2.5-
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Pro-inflammatory 
mediators 
Action Vitamin D 
neuroglia by releasing 
chemokines (Mayer et al., 2013), 
and may be involved in an 
elevated likelihood for sepsis or 
septic shock among critically ill 
patients (Moromizato et al., 
2013). 
fold increment on the risk for 
sepsis or septic shock in vulnerable 
patients.  (Moromizato et al., 
2013). 
• Vitamin D can down regulate the 
expression of TLR-8 and its direct 
gene transcription (Huang et al., 
2015).  
Glutamate 
excitotoxicity 
• Overstimulates low voltage 
calcium channel (LVCC) and 
leads to deregulation of 
intracellular calcium by 
promoting massive influx, thus 
worsening of calcium influx and 
cellular edema (Fernández-
Gajardo et al., 2014). 
• Causes necrosis and apoptosis of 
neuronal cells (Charier et al., 
2015). 
• Calcitriol significantly lessened 
damage by glutamate in cultured 
cortical neuron and glia cells. 
Pretreatment and higher doses of 
calcitriol yielded better protection 
(Kajta et al., 2009). 
• Ameliorate cell damage by 
increasing NR3 expression, 
subsequently antagonizing 
proinflammatory ERK MAPK 
pathway (Fu et al., 2013). 
Low voltage 
calcium channel 
(LVCC) subunit 
A1C 
• Up-regulation suppresses 
expression of vitamin D 
Receptor (VDR) by promoting 
amyloid- β accumulation. 
• Calcium is cytotoxic at high 
levels (Gezen-Ak, Dursun & 
Yilmazer, 2013). 
• Disrupts permeability of 
mitochondrial membrane, which 
compromises membrane action 
potential and uncouples ATP 
production. 
• Worsens oxidative stress 
(Fernández-Gajardo et al., 2014). 
• Low ATP production will lead to 
dysregulation of membrane 
transport proteins (Shi et al., 
2015). 
• Positive modulation of low voltage 
calcium channel subunit A1C 
(LVCC-A1C) has been observed in 
cultured neurons after suppression 
of VDR (Gezen-Ak, Dursun & 
Yilmazer, 2013). Downwards 
regulation of the LVCC-subunits is 
unleashed by vitamin D or VDR 
and thought to block calcium 
influx.  
• Additionally, vitamin D enhanced 
expression of calcium binding 
proteins thus limiting free ions 
inside the cell (Groves, McGrath & 
Burne, 2014). 
amyloid β 
excitotoxicity 
• Suppresses activation of vitamin 
D receptor while promoting the 
expression of LVCC-A1C.  
• Protected cortical neurons against 
toxicity from amyloid β proteins 
through suppression of LVCC-
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Pro-inflammatory 
mediators 
Action Vitamin D 
• Accumulation is strongly 
associated to the onset of 
Alzheimer disease (Gezen-Ak, 
Dursun & Yilmazer, 2013). 
A1C while stimulating the 
expression of VDR. 
• Improves amyloid β elimination 
from the brain (Gezen-Ak, Dursun 
& Yilmazer, 2013). 
Macrophage-
inflammatory 
protein-2 (MIP-2) 
release 
• A chemokine that promotes 
inflammation (Huang et al., 
2015). 
• Marked decline was mediated by 
inhibited expression of protein and 
gene transcription, and by blocking 
the phosphorylation of MAPK 
pathways (Huang et al., 2015). 
Interleukin-6  
(IL-6) 
• Is a cytokine required to activate 
astrocytes (Mayer et al., 2013).  
• Following brain trauma, IL-6 
appears to have positive effect 
on neuronal survival (Mayer et 
al., 2013), such as improving 
survival and differentiation of 
oligodendrocytes (Shi et al., 
2015).  
• Marked decline in synthesis and 
signaling at protein and mRNA 
sites (Atif et al., 2013), were 
largely mediated by vitamin D 
inhibitory effects on p38, ERK and 
JNK (Huang et al., 2015). 
• In animal experiments, deficiency 
was linked to elevated cytokines in 
the brain without a trauma, 
including IL-6 (Groves, McGrath 
& Burne, 2014). 
Blood toxicity • Blood-driven axonal 
fragmentation was noted to 
begin 12 hours after exposure 
and progressed to axonal death 
(Charier et al., 2015).  
• Initiates inflammation and 
toxicity (Chauhan, 2014).  
• Vitamin D application protected 
brain cells against blood-induced 
toxicity and this effect was 
enhanced by concomitant use of an 
N-methyl D-aspartate (NMDA) 
glutamate receptor antagonist 
(Charier et al., 2015). 
Caspase-3 • Activated by lysed mitochondria, 
this messenger is capable of 
triggering apoptosis (Atif et al., 
2013). 
• Inhibits signaling activity (Kajta et 
al., 2009). 
Peripheral 
Leukocytes 
• After infiltration, these cells 
assist neuroglia cells in the brain 
by promoting inflammation and 
produce toxic concentrations of 
nitic oxide (Fernández- Gajardo 
et al., 2014). 
• Promotes oxidative stress by 
• VDR expression and 1,25OH2D3 
activation are induced by 
peripheral and neuronal immune 
cells activation, which in turn 
controls feedback mechanisms that 
diminish possible damage from 
overactive immune reactions 
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Pro-inflammatory 
mediators 
Action Vitamin D 
increasing production of nitric 
oxide (NO) (Fernández-Gajardo 
et al., 2014). 
• Prompts additional recruitment 
of glia and peripheral immune 
cells resulting in a systemic 
immune reaction (Mayer, Huber 
& Peskind, 2013). 
(Groves, McGrath & Burne, 2014; 
Moromizato et al., 2013). 
• Deficiency is connected to 
defective actions of macrophages 
involving secretion of pro-
inflammatory cytokines and 
phagocytic performance 
(Moromizato et al., 2013). 
 
 
Anti-inflammatory 
mediator 
Neuroprotective actions Vitamin D 
NR3A NMDA 
glutamate receptor 
subunit 
 
(found in brains of 
mammals) 
• Antagonizes extracellular signal-
regulated kinase (ERK) MAPK 
pathway by phosphorylation 
CREB, a protective nuclear 
signaling protein. 
• Reduces cell membrane 
permeability to calcium. 
• Co-expressed with NR3B, 
decreases calcium influx into 
mitochondria (Fu et al., 2013). 
• Increases NR3A concentration by 
decreasing its degradation, 
consequently triggering expression 
of the calcium-response element 
binding protein (p-CREB), an anti-
apoptotic mechanism (Fu et al., 
2013). 
cAMP/Ca2+-respon
se element binding 
protein (CREB), a 
nuclear 
transcriptor factor 
• Stimulates neurogenesis, and 
may be effective in protection 
cells from glutamate 
excitotoxicity (Fu et al., 2013). 
• Increases expression, thus 
promoting cell viability (Fu et al., 
2013). 
Superoxide 
dismutase 
• Potent antioxidant enzyme 
behind the protective catalysis of 
superoxide (Ekici, Ozyurt & 
Erdogan, 2009). 
• Produced a substantial boost in 
superoxide dismutase (Ekici, 
Ozyurt & Erdogan, 2009). 
heme  
oxygenase-1 
expression 
• Produces potent antioxidant 
molecules in neuronal and 
neuroglia cells (Atif et al., 
2013). 
• Vitamin D produced a  twofold 
increment, thus attenuating 
oxidative damage after ischemic 
event (Atif et al., 2013) 
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